MedAdvisor FY16 Preliminary Results – Growth in PEP Customers, Increase of 81% in Orders Received for PEP

26th August 2016, ASX Announcement

Highlights

  • Revenue from pharmacy subscriptions and patient engagement programs (PEP) has grown by ~24% to $1.43 million, driven primarily by pharmacy subscription growth
  • Total revenue of $1.76m is 7% lower compared to FY15 which included the final licence fee payment $500,00 under the Actavis agreement
  • Gross margin from pharmacy subscriptions increased to 71%, from 43% in the prior corresponding period
  • Substantial progress reported in key operational metrics:
  • Over 180,000 patients using the platform, a 133% increase on FY15
  • Expansion of pharmacy network by 36% on FY15, to over 1,600 pharmacies
  • Growth in PEP customers, have grown to 7 manufacturers, including leading pharmaceutical companies GSK, UCB, Astra Zeneca, Novartis and Bristol Myer Squibb, with revenue uplift to be recognised largely in FY17
  • An increase of 81% in orders received for PEP compared to FY15
  • Investment made in marketing and sales teams and initiatives has strongly positioned the Company for further domestic growth and international expansion

MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, has today released its Appendix 4E and is pleased to present its maiden Preliminary Financial Report for the 12 month period ended 30 June 2016.

To read the full announcement, please click on the button below.

Peppermint Forms New Strategic Partnership in the Philippines with United Coconut Planters Bank for its Remittance Services

26th August 2016, ASX Announcement

Highlights

  • Peppermint and UCPB from strategic partnership wherein Peppermint will provide a proprietary platform termed ‘Peppermint Fast Remittance System’ to be installed with UCPB.
  • The Peppermint Fast Remittance System will be used by customers, such as Money Transfer Operators and Remittance Companies in processing international remittances to beneficiaries in the Philippines.
  • Services offered via the Peppermint Fast Remittance System will utilise the Interbank Funds Transfer (IBFT) facility in the Philippines.

PERTH, AUSTRALIA, 26 AUGUST 2016: Peppermint Innovation Limited (ASX: PIL) (“Peppermint” or “the Company”) is pleased to advise United Coconut Planters Bank of the Philippines (“UCPB”), an established and respected top tier bank in the Philippines, has entered into a strategic partnership with Peppermint to install the Peppermint Fast Remittance System, a proprietary remittance platform designed by the Company.

The installation of the Peppermint Fast Remittance System with UCPB will facilitate international remittance services using the Interbank Funds Transfer (IBFT) facility in the Philippines.

UCPB is currently using Peppermint’s platform to offer mobile banking and payment services to its account holders.

To read the full announcement, please click on the button below.

Altech Chemicals Ltd Receives Speculative Buy from Perth Broker

25th August 2016, Proactive Investors

Altech Chemicals Ltd (ASX:ATC) has received a Speculative Buy from Perth-based stockbroking firm DJ Carmichael.

The broker applied a valuation of $0.355 from $0.41 per share. The following is an extract from the report.

ECA financing steps in final throws

ATC are making good progress on their project funding application to the Federal Republic of Germany’s Export Credit Agency (ECA).

ATC are now at stage 7 of a 9 stage process that, if successful, will result in the majority of the project debt being provided at an extremely low interest rate.

In addition, ATC is seeking to increase the percentage of total project debt to be covered under export credit, thereby decreasing the repayments and increasing yearly project cash flows.

The recent successful $10m capital raise should see ATC funded through to first drawdown of the project funding Q1 CY17.

To read the full article, please click on the button below.

TFS Strong FY16 Established Platform for Transformational FY17

26th August 2016, ASX Announcement

Highlights

  • Cash EBITDA of $62.2m (FY15: $57.5m), up 8.2% on prior year and in line with guidance
  • Over 1,600ha of new plantations established in FY16, ahead of guidance
  • Completion of the third annual harvest, with more than 32,000 trees harvested – on track to deliver over 300 tonnes of heartwood, a tenfold increase on the 2015 harvest
  • Long-term contracts secured with Chinese and Indian wood buyers
  • Supply agreements now in place for the majority of harvests through to 2021
  • Strong financial platform established for further growth, with cash balance of $107.0 million (30 June 2015: $72.7 million) and debt refinance completed
  • Transformational harvest to drive at least a 25% increase in Adjusted Cash EBITDA in FY17

TFS Corporation Ltd (“TFS”, “the Company”, ASX:TFC), the world’s largest owner and manager of commercial Indian sandalwood plantations, has recorded Cash EBITDA of $62.2 million for the twelve months ended 30 June 2016, up 8.2% on FY15 and in line with guidance.

Cash revenue increased 16.1% to $175.5 million (FY15: $151.2 million), driven by increases in plantation establishment fees, sandalwood product sales, and management fee income.

Reported Net Profit After Tax was $90.1 million, down 20.3% on FY15 ($113.0 million), due mainly to a reduction in non-cash revenue that was driven by a lower net unrealised foreign currency gain on $19.0 million compared to the prior year (FY15: $55.7 million).

To read the full announcement, please click on the button below.

To view the Full Year Results Presentation, please click on the button below.

STARIN’s Adina Apartment Hotel to be Built in Macquarie Park, North Ryde

9th August 2016

154 Room Hotel to Open in Sydney’s Rapidly Growing Business District

TFE Hotels will operate a stunning new Adina Apartment Hotel in Sydney’s second biggest and fastest growing buiness and commercial district, Macquarie Park at North Ryde, for owner STARIN, a Sydney-based boutique fund manager that actively engages in prime commercial property of hotels and serviced apartments. The new Adina Apartment Hotel is STARIN’s flagship project and it will deliver design excellence and commercial retuns, fulfilling the high demand for accommodation from businesses in Macquarie Part, by being the first and tallest fully serviced apartment hotel.

STARIN’s Adina Apartment Hotel Macquarie Park designed by Group GSA, will offer sweeping views of Sydney’s city skyline from its 19 storeys and includes and infinity pool, gym and bar on the top floor. It will comprise 154 hotel apartments, a ground floor reception, cafe and bar with an outdoor area and conferencing. Construction is starting now with planned completion end of 2017.

To read the full media release, please download the file below.

MedAdvisor Launching New Feature in Collaboration with Diabetes Australia

25th August 2016, ASX Announcement

Melbourne, 25 August 2016: MedAdvisor Limited (ASX:MDR) Australia’s leading digital medication adherence company, in collaboration with the national diabetes organisation Diabetes Australia, today launches a new tool that allows people living with diabetes to order their consumable products and ensure accurate supply in pharmacy.

Under the National Diabetes Services Scheme (NDSS) – funded by the Australian Government and administeres by Diabetes Australia all NDSS subsidised diabetes consumable products, such as blood glucose testing strips, insulin pen needles and insulin pump consumables, are now only available through pharmacies. Previously, people living with diabetes were able to order their supplies online.

In anticipation of this significant change, MedAdvisor has developed and now launched customised features which will enable people with diabetes and their carers to reserve NDSS products remotely for collection from their MedAdvisor Network Pharmacy of choice. People with diabetes and carers will also be able to track their usage and supply for NDSS products and reorder these items through their MedAdvisor App or through MedAdvisor on their desktop computer.

To read the full announcement, please click on the button below.

Folkestone’s Full Year Results – Normalised Net Profit after Tax up 71.2%; Annual Report; Results Presentation; Investor Review

25th August 2016, ASX Announcement

Folkestone’s Full Year Results – 30 June 2016

  • Normalised net profit after tax of $5.0 million, up 71.2% on FY15
  • Normalised earnings per share of 3.4 cps, up 49.3%
  • Net asset value (NAV) per share of 98.9, up 13.1%
  • Gearing reduced to 4.2%, down from 15.6%
  • Funds under management of $1.05 billion, up 14.7%
  • All funds outperformed their relevant investment benchmark
  • $16.9 million unrealised gain ($11.8 million net of tax) generated from FLK’s co-investment in Folkestone Education Trust (ASX: FET)
  • Strong sales across active development projects
  • Added three new development projects to the pipeline
  • Established FLK’s Seniors Living platform
  • FLK to pay a fully franked dividend of 2.5 cps – the first dividend in 8 years

Financial Results

Folkestone (ASX: FLK) today announced a normalised net profit after tax for the 12 months ended 30 June 2016 of $5.0 million, an increase of 71.2 per cent over FY15. Statutory net profit after tax was $5.5 million, down 22.3 per cent over FY15.

Normalised earnings per share is 3.4 cents compared to 2.3 cents for FY15. Statutory earnings per share is 3.7 cents compared to 5.5 cents for FY15.

Folkestone’s Managing Directon Mr Greg Paramor said “the solid result for FY16 reflects positive contributions from both our funds management platform and our on-balance sheet development activities. It also reflects our focused and disciplined approach to implementing our strategy in an environment where capital is abundant and competition for assets is driving prices close to cyclical highs in many sectors”.

To read the full announcement, please click on the button below.

To view the Investor Review, please click on the button below.

To view the Investor presentation, please click on the button below.

To view the Annual Report, please click on the button below.

Altech Updated Research Report

25th August 2016, ASX Announcement

Altech Chemicals Limited (Altech/ the Company) (ASX: ATC) is pleased to advice of the release of an updated research report titled “ECA financing steps in final throws” by Perth-based stockbroking firm DJ Carmichael. Written by DJ Carmichael Head of Research, Mr Paul Adams, the report is follow-up from Mr Adams’ initial research report on the Company published in February this year (refer ASX announcement dated 26 February 2016).

A copy of the updated research report is now available on the Company’s website: www.altechchemicals.com.

To read the full announcement, please click on the button below.

Booodl featured in the Deloitte Retail Trends Report Vol. 1

It’s the Booodl mission to help physical retail thrive by driving shopper visits and sales for stores, brands, malls and high streets. Given that, we’re thrilled to have Booodl included in the latest Deloitte Retail trends report released yesterday.

The paper is the first in a series looking at the Australian retail sector and how retailers can adopt new technologies and better engage customers. Booodl, being one of those technologies, is featured alongside others (Myagi, Oak Labs, Fluent Retail, With.Me) looking to improve the physical store discovery and in-store experience.

Read our blog post on the report or download the full report via the Deloitte website. We’d also really appreciate if you could help amplify the report through your own networks. A couple suggestions to get the ball rolling:

  • Great to see @booodl featured in the Deloitte #RetailTrends report goo.gl/W6Upj8 #StoreDiscoveryOptimisation
  • Vol. 1 of Deloitte’s #RetailTrends report is out & @booodl is in for their work helping retailers get discovered goo.gl/W6Upj8

LatAm Autos Delivers Record Revenue Growth Across All Markets; Results Investor Presentation

23rd August 2016, ASX Announcement

Leading Latin American online auto classifieds business LatAm Autos Limited (ASX:LAA), is pleased to announce its results for the six months ended 30 June 2016 (1H 2016).

Commenting on the Company’s growth over the first half of 2016, Executive Chairman Mr Tim Handley said: “We have a focused growth strategy in place with the aim of making LatAm Autos the dominant dedicated online auto classified and content company in Latin America [excluding Brazil]. The first half results, financial and operationally, have delivered to our expectations.”

“We have continued to successfully grow market share and our products have gained strong traction, as can be seen in LatAm Autos’ revenue growth in local currencies of between 24% and 70% in each of the markets we operate in. In addition, with 186,000 listings, more dealers and higher site traffic, we are well placed to continue our growth trajectory over the second half of this year and move closer to cash flow break-even,” added Mr Handley.

1H 2016: Investing in growth

  • Revenue up 44.7% to $3.9 million (vs 1H 2015)
  • Underlying EBITDA loss of $6.0 million
  • Cash of $12.7 million at 30 June 2016

To find out more about LatAm Autos, please click on the button below.

To read the full announcement, please click on the button below.

To view the Results Investor Presentation, please click on the button below.

Aurora Labs Share Price Soars Since Listing Last Week

22nd August 2016, AFR by Trevor Sykes

Float of the Week

To Aurora Labs (A3D) whose 20¢ shares were listed on August 16 and by August 18 had soared to 90¢. The company raised $2.8 million to pursue innovative proprietary technologies for 3D metal printing.

Three-dimensional printing? According to the prospectus, a 3D image is processed into digital slices, which are fed sequentially into a printer. Then lasers lay down layers of print corresponding to the images received.

It all sounds highly fictional to me, but the punters must believe it because in two days of listing A3D was a four-bagger.

To read the full article, please click on the button below.

Perth Startup Aurora Labs Goes Public after Raising $2.8 million

18th August 2016, Startup Smart by Denham Sadler

Perth-based 3D printing startup Aurora Labs is officially a public company, listing on the ASX on Tuesday morning after successfully raising $2.8 million through an IPO.

Aurora Labs develops a range of metal 3D printers that it says are far cheaper than its competitors.

The startup offered 14 million shares at 20 cents each to raise the $2.8 million after lodging a prospectus in June.

Aurora Labs opened its first day of trading at 54 cents and closed on Wednesday at 70 cents.

Aurora Labs CEO David Budge says it’s an “exciting” moment for the early-stage tech company.

“The whole process of moving from private to public is a fairly steep learning curve for anybody,” Budge tells StartupSmart.

“It’s been a very good process overall and we’re certainly very happy with the results in the end.

“There’s a lot of interest in the company moving forward and this is a fairly significant milestone. We’re only two years old and this is a big stepping stone.”

The cash injection from the listing will be used to bring Aurora Labs’ small format 3D printer to market and further the development of the medium and large models, Budge says.

“The idea behind it is to take the technology we’ve developed with the small format printer and get it into the marketplace,” he says.

“We’ve reached the end of the beta testing phase and we’re moving into production.”

He says he originally set out to raise a round of private funding to facilitate this but after encountering difficulties decided to turn to the public markets.

“We examined the private route extensively and that was our preferred method originally,” Budge says.

“We found it difficult to get funding in Australia. If we had been in the US we would’ve found it somewhat easier but we were keen to keep it as an Australia company so we decided on IPO funding for the next level.”

To read the full article, please click on the button below.

YPB First Commercial Contract in Mexico

24th August 2016, ASX Announcement

Brand Protection and Customer Engagement solutions company YPB Group Limited (ASX: YPB) has secured its first commercial contract in Mexico through its joint venture (JV) with Affyrmx Group.

The initial contract value is US$130,000, with YPB’s proprietary tracer solution to be used to PROTECT redeemable food coupons that are frequently the subject of counterfeit. The end client is actively engaged in programs supporting people in need.

Earlier this year YPB entered a JV with Affyrmx with an initial focus on Government Vital Documents in Mexico. To date YPB has received contracts to supply Vital Records to four Mexican states, with outstanding opportunities across all of the country’s 32 states, governing a population of more than 120 million.

While continuing to develop opportunities in the government sector Affyrmx is now actively pursuing deals in the commercial sector with YPB.

To read the full announcement, please click on the button below.

Craig Farrow Joins Bulletproof Board

24th August 2016, ASX Announcement

Bulletproof Group Limited (ASX:BPF) welcomes Craig Farrow to the board as a non-executive director, effective today. Mr. Farrow has also accepted the role as chair of the Audit and Risk Committee.

Mr. Farrow is a Fellow of Chartered Accountants Australia New Zealand (CAANZ), Australian Institute of Company Directors (AICD) and Australian Institute of Management (AIM), whilst also a certified participating manager and holds a Diploma of Financial Services. A founding Partner of Brentnalls SA, he is now Chairman and continues as a partner of that firm.

Mr. Farrow is currently the deputy chairman of Vocus Communications, following its merger with M2 Group, where he held the Chairman role since 2006, having been part of the founding team of M2 in 1999. He is also a director of a number of private and unlisted public companies in the agribusiness, technology and professional services sectors.

To read the full announcement, please click on the button below.

Proteomics International Expands Diagnostics Portfolio to Endometriosis

24th August 2016, ASX Announcement

Life sciences company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is applying its disruptive proteomics technology platform to new areas of significant unmet medical need.

  • PILL is investigating protein ‘fingerprints’ that can diagnose endometriosis from a simple blood test.
  • Endometriosis affects one in ten women in their reproductive years and costs Australia $7.7 billion annually.
  • The research employs PILL’s proven Promarker platform, which has already been used to develop a predictive test for diabetic kidney disease, and could deliver results within 12 months.

Perth company PILL is investigating proteins in the blood that are associated with endometriosis, paving the way for the development of a quick and easy diagnostic test for the painful condition.

Endometriosis occurs when the tissues that line the uterus spread and surround other organs. The condition affects one in ten women in their reproductive years (15-49) and costs $12,000 per year for every person diagnosed – both incidence and health burden are comparable with diabetes.

To view the full announcement, please click on the button below.

Bulletproof Delivers Record Growth: Revenues Up 69%; Full Year Presentation; Full Year Financial Report

24th August 2016, ASX Announcement

SYDNEY, Australia – Bulletproof Group Ltd (ASX: BPF) is pleased to announce its results for the 12 months ended 30 June 2016 (FY16) that saw the Company deliver record growth in revenue and solid profit performance.

FY16 Results

  • Full year revenues $47.2m, up 69% on FY15, 31% organic growth
  • Underlying EBITDA $4.7m, up 13% on FY15
  • Underlying EBIT $0.9m, up 2% on FY15
  • Underlying NPAT $0.8m, up 51% on FY15
  • Operating cash flow $5.1m, up 49% on FY15

Highlights

  • Successful integration of professional services acquisition, providing strong revenue growth
  • Completed acquisitions of Infoplex and Cloud House
  • Successful deployment of Sell Anywhere product with major retailer
  • Significant new blue chip customer wins, with over 750 customers now in the portfolio

Commenting on the FY16 results, Bulletproof Group’s CEO Anthony Woodward said:

“We are pleased to have been able to deliver another year of strong organic growth. When combined with our acquisitions, it has been a record year for overall revenue growth, which was up 69 per cent to $47.2 million, as a result. This reaffirms that our strategy is delivering responsible growth, product superiority and service excellence from a commanding, market-leading position.”

To view the full announcement, please click on the button below.

To view the Full Year Presentation, please click on the button below.

To view the Financial Report, please click on the button below.

Altech Receives Loan Indicative Terms and Conditions

24th August 2016, ASX Announcement

Highlights

  • Altech receives lenders first draft indicative term sheet
  • Altech targeting total project debt of US$70 million
  • Export credit cover (ECA) component of US$60 million
  • Sole lender structure proposed for the entire debt portion of up to US$70 million
  • Simplified debt financing and attractive ECA-covered component

Altech Chemicals Limited (Altech/the Company) (ASX: ATC) is pleased to announce that the Company has received a summary of senior facility agreement indicative terms and conditions from German government-owned KfW IPEX-Bank for the proposed US$70 million of debt financing of its Malaysian high purity alumina (HPA) project.

The indicative terms and conditions proposed by KfW IPEX-Bank includes matters customary for the type of project debt financing being targeted, such as description of credit facilities; interest rates and fees; debt payment terms and maturity dates; collateral security; affirmative and negative covenants; details of guarantors; closing conditions; financial covenants; representations and warranties; events of default and material adverse changes. The details for these matters and potential adjustments are currently under discussion and will take into account the results from the ongoing due diligence process where necessary, before being submitted for approval within the German export credit agency and KfW IPEX-Bank.

To view the full announcement, please click on the button below.

QBiotics Share Offer Update: View Investor Presentation Online; Share Offer Progress; Seven News Story; Frequently Asked Questions Answered

QBIOTICS SHARE OFFER UPDATE
The QBiotics Share Offer has now been open for 1 week. Below is an update on how it is progressing, as well as links to further useful information and FAQs about the Offer.

UPDATE ON SHARE OFFER PROGRESS
The QBiotics Share Offer opened on Monday 15th August and has been very well received. It is already over 50% subscribed and we expect it will close in the coming weeks. Should the Offer close early, we will inform you in advance.

If you intend to apply for shares in this Offer, and have not done so already, we encourage you to do so ASAP. You can apply for shares via the Share Offer site www.qbiotics.com/prospectus.

Shares are $0.40 and the minimum investment is $5,000 (12,500 shares).

INVESTOR PRESENTATION VIDEO AVAILABLE TO VIEW ONLINE
Given that some investors could not attend the recent Investor Roadshow Presentations, we recorded it and it is now available to view. Please click below to view this video.

SEVEN NEWS STORY ON EBC-46
On Monday 15th Aug, Seven National News ran an exclusive story on the human trial results of EBC-46. It was watched by over 1.9m people. If you missed the story, you can watch it below.

The Cairns Post also ran a story on QBiotics yesterday. You can view it HERE.

There is more media planned for QBiotics in the coming weeks. As the stories are published we will upload them to the QBiotics Offer site under the Media section.

PRINTED COPY OF PROSPETUS
A printed copy of the Prospectus was posted to all QBiotics shareholders yesterday. If you are not an existing QBiotics shareholder and would like a printed copy, please email info@axstra.com.au and include your name, mailing address and phone number. We will post it to you free of charge.

FREQUENTLY ASKED QUESTIONS
Since the Offer opened, we have received many questions about the Share Offer and the Application process. Below are some of the most frequently asked questions, along with answers:

QUESTION ANSWER
Which online Application Form do I use? If you are an existing QBiotics shareholder, use the Priority/Existing Shareholder application button, located on the right side of the Offer website. Enter your Entitlement Number and details to apply. Shareholders were emailed their unique Entitlement Numbers on Monday 15th Aug. If you did not receive your Entitlement number, or have lost it, please email info@axstra.com.au to request it.If you are not an existing shareholder, please use the General application button.
If I pre-registered, but am not a QBiotics shareholder, will my application still be prioritised? If you pre-registered for the Share Offer, but are not an existing shareholder, you must use the General Offer to apply for shares. However should the Offer be oversubscribed, your application will still be prioritised over those who did not pre-register. The Offer Manager holds the list of everyone who pre-registered and this will be cross checked when the Offer closes.
If I’m an existing shareholder, can I apply for shares under a different entity? Yes, you can. To apply for Share under a different entity to your existing shareholding in QBiotics, simply use the General Offer button on the Share Offer site. Once you have completed the application, email reuben@axstra.com.au and notify him that you are an existing shareholder, and that you have applied for shares as a different applicant. Reuben will mark your new application as an existing shareholder and you will be prioritised in the Share Offer.
Do I have to use BPay to pay for Shares? Yes. If applying via the Offer Site, the only way to pay for Shares is via BPay. By using BPay your unique BPay code is matched with your application. There is no option to transfer funds via EFT or any other means. If this is a problem, please contact Offer Manager Reuben Buchanan on reuben@axstra.com.au to discuss options.
If I’m an overseas investor, can I apply in the QBiotics Share Offer? Due to Australian laws related to capital raising, only Australian residents can apply for shares in the QBiotics Share Offer under the current Prospectus.
When will the Offer close? The Offer is scheduled to close on the 9th September. However, if the Offer is fully subscribed prior to the 9th of September the Offer may close early. If it is likely to close early, we will notify all applicants, shareholders and those who preregistered in advance.

PRINTED APPLICATIONS
Although we encourage all investors to apply for shares via the Share Offer site, it is possible to apply using a physical Application Form contained in the Prospectus. If you wish to apply for Shares this way, please do so ASAP and mail the Application Form, along with a cheque as per the instructions contained on the Application form.

CONTACT
Once again if you have any enquiries or need help with anything relating to this Share Offer, please contact Offer Manager Reuben Buchanan at reuben@axstra.com.au.

Anti-Cancer Drug Discovered in Rainforest Successfully Tested on Humans

22nd August 2016, The Cairns Post by Daniel Bateman

A POTENTIAL cancer cure discovered in Far North Queensland that has been successfully tested on human patients is hoped to become commercially available in four years.

Brisbane-based researchers QBiotics have released the ­results of their first clinical trials of the drug EBC-46.

The drug has been derived from the seeds of the rainforest blushwood tree, which grows on the Tablelands.

Eight cancer patients across Australia were tested with the drug, which successfully treated four different types of ­tumours that included melanoma, squamous cell carcinoma, basal cell carcinoma, and breast adenocarcinoma.

QBiotics CEO Dr Victoria Gordon said none of the ­patients, who were treated at hospitals in Brisbane, Sydney, Melbourne and Adelaide, showed any negative side ­effects from the drug.

“Our last patient – which was our melanoma patient – we had total tumour destruction in both of the tumours that we treated,” she said.

“We’re very happy about that.

“Within seven days, the ­tumours were gone.

“The exciting thing is the drugs are responding in exactly the same way in tumours in cats and dogs and horses.

“It’s proving our theory that it’s not species-specific, and it’s not tumour-specific either, ­because it’s actually working in a range of tumours.”

To read the full article, please click on the button below.

Kordia and Thinxtra Internet of Things Network Passes Halfway Mark

22nd August 2016, Scoop Media

Business-focused service provider Kordia together with partner Thinxtra, says the deployment of a dedicated new Internet of Things (IoT) network, being established nationwide, has officially passed the halfway mark.

The opening of a major new site in Hamilton last week pushed the outdoor coverage of the network to 50 per cent of New Zealand’s population.

The network also racked up an unofficial world record for the greatest distance over which data has transmitted on a SIGFOX IoT network to date, with data sent 212 kilometres between a Kordia site in North Canterbury and another in Wellington.

“The transmission surpassed a previous distance record of 195 kilometres, which occurred between the Pyrenean Mountains and Toulouse in France”, says Aaron Olphert, Kordia’s CTO.

Darren Robinson, who heads global sales and marketing at cornerstone investor Rakon, says the go-live of Hamilton is a significant milestone which further validates the Kiwi tech company’s decision to invest with Thinxtra.

“The Hamilton site ensures comprehensive coverage for the Golden Triangle region of Auckland, Waikato and the Bay of Plenty,” says Robinson.

“This area is home to some of New Zealand’s most important primary producers, as well as the country’s most important logistics hubs.

“The IoT has the potential to revolutionise these industries and turbocharge the contribution they make to New Zealand’s economy, and we are delighted to play our part in realising that potential.”

To read the full article, please click on the button below.

Charter Hall Achieves 29% FUM Growth to $17.5 billion; Annual Results Presentation; Full Year Financial Report

22nd August 2016, ASX Announcement

Charter Hall Group (ASX:CHC) (Charter Hall or the Group) today announced its full year results for the 12 months to 30 June 2016. Key financial and operational highlights for the period are:

Financial highlights:

  • Statutory profit after tax of $215.2 million, up $97.3 million
  • Operating earnings of $124.7 million, up 26.2%
  • Operating earnings per security of 30.4 cents, up 10.5%
  • Distribution per security of 26.9 cents, up 11.2%
  • Net Tangible Assets per security of $3.04, up 10.1%

Operational performance:

  • Access: Gross equity inflows of $1.5 billion from diversified equity sources.
  • Deploy: Completed $3.7 billion of property transactions. $3.0 billion in acquisitions, $0.7 billion in non-core divestments.
  • Manage: 29% growth in funds under management (FUM) to $17.5 billion. Completed 545 leasing transactions.
  • Invest: Net $56 million invested alongside our capital partners. 6.46% WACR and 7.9% discount rate. Property Investment earnings growth of 26.4%.

Charter Hall’s Group CEO and Managing Director, David Harrison said: “Growth of 29% in FUM to $17.5 billion and 10.5% OEPS growth reflects the Group’s strategy focusing on accessing, deploying, managing and investing capital.”

To view the full announcement, please click on the button below.

To view the Annual Results Presentation, please click on the button below.

To view the Full Year Financial Report, please click on the button below.

Placer Property Investor Newsletter

Placer Property has launched The Stables Property Fund. The development of the Centre was managed by Placer Property and was opened in April 2015.

The Stables Shopping Centre is a new 5,605 square metre convenience based, neighbourhood shopping centre anchored by a large format Woolworths Supermarket and BWS liquor outlet. The Stables also accommodates a range of specialty tenants including cafes, a hairdresser and take away food outlets, as well as offering parking for 260 car directly in front of the centre.

The Stables Shopping Centre is located in Golden Grove, approximately 22 kilometres northeast of the Adelaide CBD. It is located on a highly visible corner site at the intersection of Golden Grove Road and Crouch Road in an affluent trade area.

Key features of the Fund include:

  • 7.60% Forecast Yield in FY16 and FY17
  • Woolworths as anchor tenant
  • WALE of 11 Years by rental income
  • High initial forecast $0.95 Net Tangible Asset per Unit

Oncosil Medical Investor Presentation August 2016

22nd August 2016, ASX Announcement

Overview

  • Developing an implantable radiotherapy medical device ‘OncosilTM’ for pancreatic and liver cancer
  • CE Mark targeted in the near term followed by commercial launch and sales in UK, EU and Australia
  • Technology platform suitable for multiple solid state tumours providing a more targeted therapy
  • Global pancreatic cancer market > US1$B
  • Global Pivotal Study underway – FDA approved IDE – July, 2016 Trial sites being engaged
  • New leadership team – Daniel Kenny CEO (ex Baxter, Roche) and Dr Chris Roberts (ex Cochlear CEO) Chairman-elect
  • Proprietary technology with robust patient portfolio
  • ASX listed ~ $69m market cap and $13.4m of cash

Device Overview: Radiation therapy delivered directly into the tumour

  • Pure “soft beta” radiation source (P32) to avoid systemic side effects
  • Localised radiation therapy using “sticky” microparticles
  • Carrier particles are inert silicon
  • Particles are suspended in fluid to allow direct injection into the tumour
  • Single Injection under anesthesia takes 30 minutes
  • Local radiation in the tumour lasts around 3 months

To view the full Presentation, please click on the button below.

Crowd Mobile to Raise $3 Million Via Placement & Rights Issue

19th August 2016, ASX Announcement

Highlights:

  • A$2.4 million raised through a share placement
  • A$1.0 million Rights Issue which is partially underwritten
  • Funds raised will support our ongoing marketing initiatives, investments in product development and earnings growth strategy.

Crowd Mobile Limited (ASX:CM8 & FWB-XETRA:CM3, Crowd Mobile, “the Company”) is pleased to announce that it has received commitments from sophisticated and professional investors to subscribe for A$2.4 million of new and  fully paid ordinary shares in the Company at 16 cents per share with a 1 for 2 free attaching option exercisable  at 27 cents, expiring 2 year from the date issue (“Share Placement”).

Crowd Mobile also announces a Non-Renounceable Rights Issue to raise A$1.0 million on the same terms as those of the Share Placement (“Rights Issue”). A$0.6 of the Rights Issue is being underwritten by DJ Carmichael Pty Limited (“DJC”), which combined with the Share Placement raises A$3.0 million in total.

To view the full announcement, please click on the button below.

BPS Delivers Record FY16 Results & Security Purchase Plan

18th August 2016, ASX Announcement

Highlights:

  • Robust business development drives record revenue of more than $50 million
  • Investment in bolstered salesforce drives EBITDA of $9.5 million
  • Transformational acquisition of Entertainment to boost FY17 revenue by 118% and drive projected EBITDA growth of 49% in current year
  • Final dividend of 2.0 cents per share taking full-year dividends to 4.0 cents per share

Leading channel enablement and payments platform provider BPS Technology Limited (“BPS”, “BPS Technology” or “the Company”) is pleased to release full year results for the year ending 30 June 2016 (FY16).

In its second year of operation since listing on the ASX in September 2014 the Board set some ambitious goals for BPS 2016.

To view the full results, please click on the button below.

To view the Share Purchase Plan, please click on the button below.

Instituional Investment Survey Meme Again Beats Top Performing Funds

An article in today’s Money Management newsletter reported on the results of a recent Institutional Sector Survey which listed the top performing Australian Equity funds (on the basis of their before fee returns) for the year to the end of July 2016. As a boutique fund the Meme Australian Share Fund’s current assets under management of $5.8 million are below the threshold for inclusion in these results, however the chart below shows how our Fund fared over the same period when compared (on an after fee basis) to the quoted current leaders (data sourced from FE Analytics).

 

 The Meme Australian Share Fund invests in listed Australian equities outside the ASX20 and takes an evidence-based quantitative approach to investing.  The Fund employs a robust and back-tested trend-following strategy to identify investment opportunities expected to provide both positive price appreciation and relative price out-performance over the medium to long term while maintaining a strict risk-management regime to limit losses in any market downturn. The Fund remains open to new investment.

Hot Calibration Run of the OncoSil Device

18th August 2016, ASX Announcement

OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company), a late stage medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to announce that it has successfully completed a supply chain validation process including the first hot (radioactive) calibration delivery of OncoSil™.

In preparation for the commencement of the Company’s planned global clinical study of OncoSil™ for the treatment of pancreatic cancer (Oncopac-1) and the commercialisation of OncoSil™ subject to attainment of CE Mark, the Company restarted de-novo manufacturing of OncoSil™ microparticles in January 2016. The manufacturing, supply chain validation and delivery to clinical and commercial centres of OncoSil™ product is a key step to commercial sales and the treatment of patients in the OncoPac-1 Study.

To view the full announcement, please click on the button below.

Proteomics Secures First Commercialisation Deal for PromarkerD

18th August 2016, ASX Announcement

Life sciences company Proteomics International Laboratories  (ASX: PIQ) (PILL) has signed an exclusive license for its PromarkerD assay for the diagnosis of diabetic kidney disease in the Dominican Republic in Central America.

Highlights:

  • Diabetic kidney disease test to be commercialised in the Dominican Republic in a deal worth in excess of USD 1.5 million.
  • The agreement marks the first international licensing deal for the PromarkerD assay.
  • Manufacturing will occur in US Territory of Puerto Rico and the deal paves the way for other markets including the United States, China and Japan.

The licence granted to Omics Global Solution (Omics) for the Dominican Republic for the PromarkerD assay will provide significant economic benefit to PILL. Although the Dominican Republic has only 10.6 million people, the net present value of financial terms in excess of USD 1.5M for the first nine years of the agreement.

To view the full announcement, please click on the button below.

YPB Signs Contract With Major Beijing Museum

17th Augus 2016, ASX Announcement

  • YPB to sell invisible anti-counterfeit tracer technology to newly developed Art Museum in Beijing

Brand Protection and Customer Engagement solutions company YPB Group Limited (ASX: YPB) has signed a contract with a leading art museum in Beijing to PROTECT it with YPB’s anti-counterfeit tracer technology.

YPB’s invisible tracer will be applied to the museum’s entrance tickets, with YPB’s scanner technology being used to authenticate tickets at the point of entrance.

The contract is expected to deliver approximately A$200,000 revenue to YPB in the first year.

To view the full announcement, please click on the button below.

Altech Targets US$70m Project Debt for Malaysian HPA Plant

17th August 2016, ASX Announcement

Highlights:

  • Altech targeting total project debt of US$70 million
  • Export credit cover (ECA) component increased to US$60 million
  • Residual debt component now up to US$10 million
  • Sole lender structure proposed for the entire debt portion of up to US$70 million
  • Simplified debt financing and attractive ECA-covered component

Altech Chemicals Limited (Altech/the Company) (ASX: ATC) is pleased to announce that the Company’s targeted debt financing for its proposed Malaysian high purity alumina (HPA) project has increased to US$70 million (previously $60 million).

The export credit cover (ECA) component to be covered by the German export credit agency (ECA), Euler Hereme Aktiengesellschaft (Euler Hermes) has increased from US$40 million to US$60 million.

To view the full announcement, please click on the button below.

Actinogen Receives Offer to Purchase All Less Than Marketable Parcels of Shares

16th August 2016, ASX Announcement

The Board of Actinogen Medical Limited (ASX: ACW) (Actinogen or the Company) is pleased to announce that it has received an offer from an Australian financial services licensee to purchase all less than marketable parcels of shares in the Company for $0.0645 per share (Offer).

A less than “marketable parcel” (defined in the ASX  Listing Rules as a parcel of shares with a market value of less than $500) will be any shareholding of 8,928 shares or less (Less than Marketable Parcel) on the record date. The record date for the purpose of establishing holders of Less Than Marketable Parcels has been set at close of trade on 15 August, 2016 (Record Date).

As at the Record Date, over 515 of the Company’s approximately 1,864 shareholders held Less Than Marketable Parcels, making up approximately 0.34% of the Company’s fully paid ordinary shares on issue.

To view the full announcement, please click on the button below.

YPB Extends e-Passport Agreement

16th August 2016, ASX Announcement

Brand Protection and Customer Engagement solutions company YPB Group Limited (ASX: YPB) has exercised the option to extend the Memorandum of Cooperation (MOC) with Foilmakers Australia Pty Ltd (FMA) relating to the application of proprietary VariSec technology to e-Passports.

Singed in July 2015, the first year of the agreement has resulted in four order including re-orders for YPB’s VariSec technology, to be applied to newly issued e-Passports for both first world and emerging economies. Continued orders are expected over the next 12 months.

YPB’s VariSec technology has now been applied to three countries’ e-Passport in a marketplace where an estimated 125 million new e-Passports in a marketplace where an estimated 125 million new e-Passports are issued annually.

To view the full announcement, please click on the button below.

Get Picked Up Logistics Aims at East Coast Disruptive Aggregation

11th August 2016, Fully Loaded by Rob McKay

While parcel disruptors have garnered Australian headlines recently, those looking to shake up interstate haulage and metro-distribution are less common.

Enter GPU Logistics, which founder and CEO Daniel Rombouts says is looking to use a technology proven in personal transport to tackle, initially, full trailer load east coast line-haul movements and local Sydney Metro deliveries.

The service will focus on work opportunities for tow operators, singles and B-doubles.

“GPU Logistics is a disruptive transport business using technology to aggregate owner drivers and small fleet operators Australia-wide providing them with access to extra loads, whilst at the same time servicing clients with a fully compliant operator network and the ability to reduce transport costs through the use of technology,” Rombouts says.

To view the full article, please click on the button below.

Omni Market Tide Corporate Presentation August 2016

16th August 2016, ASX Announcement

What We Do 

The Omni Market Tide group produces applications for digital stakeholder engagement. We develop products for enterprise organisations that require professional level, deep engagement applications to help solve complex business problems, and meet regulatory, governance or compliance requirements in their business.

OMT works with both cyber security and physical access providers to extend security and access applications out to mobile devices. Identity and security management are key to our applications.

Why OMT?

  • We have developed application for the leading Australian communication provider
  • We have developed corporate governance applications for one of the big four banks
  • We have developed applications or the investor space
  • We understand enterprise challenges of access to information
  • Physical and identity access via mobile devices
  • We understand enterprise ERP and access control systems

To view the full Presentation, please click on the button below.

Martin Aircraft Company Board and Management Changes

16th August 2016, ASX Announcement

As advised 2 August 2016 Business Update, the Board of Martin Aircraft Company  (MACL or the Company) has been undertaking an in-depth review of the Company’s progress, in particular focusing on how best to both progress the path towards commercialisation of the Series 1 Jetpack whilst effectively managing its costs base. KuangChi Science Limited (KCS), the Company’s cornerstone shareholder, has been consulted as part of this review process.

KCS has investments across a broad array of technology companies. In order to create synergy and lower cost across their investment portfolio KCS has established a Global Community of Innovation (GCI). In essence a group that will explore ways to share services to lower the costs, and leverage technology, across each of the disruptive technology companies within their investment portfolio.

Peter Coker, CEO and Managing Director of MACL, will be stepping down from his role and taking up a newly created role with KCS as their Vice President Global Community of Innovators Business Unit (GCI). James West, currently CFO, has appointed to CEO of MACL.

To view the full announcement, please click on the button below.

Long Pipes Semi Finalist in the Australian Technology Competition

15th August 2016

Long Pipes has developed, demonstrated and installed the Fluid Highway™ the “World’s first” continuous composite pipe made in the field without a joint for 1km or 1,000kms. It is the lowest cost, lightest, strongest, lowest CO2, lowest environmental impact, lowest labour and fastest to install fibre composite pipe globally.  The Fluid Highway ™ is unique it is tough, strong, flexible, designed to withstand extreme corrosion, erosion, temperature variations and pressures up to 130 Bar so far.

Long Pipes is now a semi-finalist in the Australian Technology Competition that will be awarded at the Darling Harbour Maritime Museum on the 2nd of November.

Australian Technology Competition

  • 38 of Australia’s leading technology companies short listed into the Australian Technologies Competition (ATC) Business Accelerator
  • Exceptional quality of entrants taking world leading innovation to global markets
  • Industry leading innovators in the sectors of energy, manufacturing, food & agritech, mining, medtech & pharma, cyber security and smart cities

The Australian Technologies Competition (ATC) has today shortlisted thirty-eight of Australia’s most exciting technology companies for the ATC16 Business Accelerator. These Semi Finalists are industry leading innovators with the capability to become game-changers across the sectors of energy, manufacturing, food & agritech, mining, medical technologies, cyber security and smart cities.

The judging panel features the country’s leading experts in commercialisation, finance, intellectual property and technology development from companies such as Deloitte, Bird&Bird and FB Rice. With a focus on building global success stories, the judges are looking for not only the best technologies but also the best managers and the best business plans.

This year’s 146 entries have jointly spent $190 million to date developing their technologies and have over 600 employees. Whilst many of the Semi Finalists are already selling solutions, they are jointly seeking an additional $80m to bring all the solutions to market.

To download the full article, please click on the link below. 

QBiotics Channel 7 News Feature: Scientists Find Australian Berry to Cure Cancer

15th August 2016, 7 News

A berry found on Australia’s Blushwood tree in the far north is believed to cure many types of cancer. Scientists made the breakthrough with EBC46 making tumours disappear in just 48 hours.

ABOUT QBIOTICS LIMITED

QBiotics Limited is developing a pipeline of promising drugs in the area of cancer and wound healing. Its lead drug, EBC-46, targets solid tumours and is currently in late pre-clinical development in preparation for a Human Clinical Phase I/II trial with the USA’s FDA. EBC-46 is also in late stage development for the veterinary market through the USA’s FDA-CVM.

QBiotics Share Offer is Now Open

We are pleased to inform you that the QBiotics Share Offer is now Open.

The Offer Site on the QBiotics website is now open where you can:

  • Download the replacement Prospectus
  • Apply for shares via the online application process

Go to www.qbiotics.com/prospectus to view the Offer Site or click the Request Offer button blow.

Key Offer Details

Offer Share Price $0.40 per share
Minimum Investment $5,000 / 12,500 shares
Total amount to be raised $10m (up to $2.5m in oversubscriptions)
Offer Opening date 15th Aug 2016
Offer Closing date 9th Sept 2016

 

Investor Roadshow Presentations

We are conducting a series of Investor Roadshow Presentations throughout Australia.  At these presentations, CEO Dr Victoria Gordon will provide an update on recent company activities, and on the development of our anticancer drug EBC-46 and wound healing treatment WH-1.

Below is the Roadshow schedule. These presentations are open to all QBiotics shareholders and interested investors. To attend, please register via the link below.

Date City Time Location Register
Mon 15th Aug Brisbane 6pm to 7.30pm Hilton Brisbane, 190 Elizabeth St, Brisbane CLICK HERE to register for this event
Tues 16th Aug Sydney 6pm to 7.30pm Hilton Sydney, 488 George St, Sydney CLICK HERE to register for this event
Wed 17th Aug Melbourne 6pm to 7.30pm InterContinental Hotel, 495 Collins Street, Melbourne, CLICK HERE to register for this event
Mon 22nd Aug Cairns 6pm to 7.30pm Hilton Cairns, 34 Esplanade, Cairns CLICK HERE to register for this event
Tues 23rd Aug Adelaide 6pm to 7.30pm Hilton Adelaide, 233 Victoria Square, Adelaide CLICK HERE to register for this event

Exclusive Story On Channel 7 News 

Channel 7 News will be airing an exclusive story on QBiotics about the progress of the Human Trials for EBC-46. This will air on the 6pm News tonight (Mon 15th Aug). Please tune in to watch this story.

If you miss the story, you will be able to view it on their website https://au.news.yahoo.com/ fter it has aired.

 

MedAdvisor Signs MoU with Glaucoma Australia Partnership to Assist 300,000 Australians

15th August 2016, ASX Announcement

Highlights

  • MedAdvisor has signed a Memorandum of Understanding with Glaucoma Australia, the leading not-for-profit patient support organisation for people living with glaucoma
  • Glaucoma Australia will become a MedAdvisor Health Association Partner and promote the MedAdvisor platform to more than 300,000 Australians estimated to have glaucoma
  • Builds on MedAdvisor’s growing Health Partner network, providing strong third party validation and support from recognised health association bodies

MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce that it has signed a Memorandum of Understanding (MoU) with Glaucoma Australia Inc, to help improve medication adherence in patients living with glaucoma.

Glaucoma Australia is the peak not-for-profit patient support organisation for people living with Glaucoma in Australia.

To view the full announcement, please click on the button below.

BPS Makes Transformative Acquisition of Entertainment Publications & Investor Presentation

12th August 2016, ASX Announcement

Highlights:

  • BPS to acquire Entertainment Publications Australia and New Zealand, a leading business -to-consumer (B2C) deals platform which produces the Entertainment Book and the Entertainment Digital Membership
  • Acquisition set to boost BPS’ growth profile with FY17E pro forma revenue growth of 118% and FY17E pro forma EBITDA growth of 49%. Significant future growth potential with the combined BPS group benefiting from a network of 36,000 SMEs, 18,000 NFPs and 550,000 paying customers (“Members”)
  • BPS successfully completes institutional placement, raising $27.5 million to fund the Entertainment acquisition and to provide growth / working capital
  • Institutional placement was significantly oversubscribed with strong demand received from institutional and sophisticated investors
  • All eligible BPS shareholders invited to participate in a non-underwritten Share Purchase Price Plan at the same price as the placement ($0.94)

Leading channel enablement and payments platform provider BPS Technology Limited (“BPS”, “BPS Technology” or “the Company”) is pleased to announce the successful completion of its underwritten $27.5 million institutional placement.

To view the full announcement, please click on the button below.

To view the Investor Presentation, please click on the button below.

Revolutionary 4Dx Locks Major Deal with Top US Hospital

11th August 2016, Australian Anthill Bu Gerald Ainomugisha

Australian medtech start-up, 4Dx is a step closer to the integration of its visionary and breakthrough technology into everyday healthcare through its latest hardware sale to leading U.S. hospital, Cedars-Sinai Medical Center, a California nonprofit public benefit corporation.

Cedars-Sinai has received a grant award of US $600,000 from the United States National Institutes of Health for the purchase of 4Dx’s new preclinical lung scanner, making Cedars-Sinai the first institution scheduled to purchase this advanced instrument, which can help detect lung diseases in their early stages.

The new scanner addresses a dilemma of current antiquated technologies in measuring the impact of cystic fibrosis, asthma, COPD, emphysema and other disorders on the lung.

To view the full article, please click on the button below.

Bill Gates Backs Aussie Biotech Start-Up Atomo Diagnostics

11th August 2016, Sydney Morning Herald By Brian Robins

In a rare public display of support for Australian technology, a large US investment fund backed by Microsoft founder Bill Gates has taken a stake in a local biotech start-up.

Launched in 2010 and based in a converted toolshop in Leichhardt, in Sydney’s inner west, Atomo Diagnostics has developed a testing platform which is making inroads into the industry globally. Winning the backing of the Gates-backed fund sends a strong message to biotechs worldwide, Atomo Diagnostics founder John Kelly said.

The fund raising has reduced the stakes of Atomo’s two main holders – Kelly and Sydney businessman Lang Walker – to below 30 per cent each, with both ending up with a ”smaller share of a bigger pie”, Mr Kelly, who is also the chief executive, said.

“It sends a very strong message to the global market,” Mr Kelly said of the Gates-backed fund’s decision to support his company. “Atomo is one of the few groups it has invested in directly.”

To view the full article, please click on the button below.

Folkestone Maxim A-REIT Securities Fund July 2016 Monthly Report

Monthly Report
July 2016
Over the 12 month period ended 31 July 2016, the Fund returned +26.25% (after fees, before tax), outperforming the Benchmark return of +24.23% by +2.02%.
The July 2016 Monthly Report provides a snapshot of the Fund and the A-REIT sector’s performance.

Atchinson Consultants Reconfirms Recommended Rating
August 2016
Atchison Consultants has reconfirmed its Recommended rating in its annual review of the Folkestone Maxim A-REIT Securities Fund.
Key strengths identified by Atchison Consultants included:

  • Experienced investment team with successful track record of managing
    A-REIT Funds.
  • A strong qualitative approach to investing with a distinct focus on management capability and behaviours.
  • Sustainable long term performance has continued in the past twelve months reflecting adherence to their investment philosophy.
  • High profile provides quality access at Board and management level within investable universe.

The Folkestone Maxim A-REIT Securities Fund is a high conviction, actively managed fund, that gives investors exposure to a mix of quality listed A-REITs that own assets across the retail, residential, commercial, industrial and real estate related social infrastructure sectors.

  • Investment Expertise
  • Exposure to Listed Real Estate
  • High Conviction, Active Strategy
  • Daily Liquidity
  • Quarterly Distributions
  • Strategic Capacity Limit

BioDiem Complete Successful Entitlement Offer

9th August 2016, BioDiem

BioDiem advises that it has now successfully completed the issue and allotment of entitlement and shortfall convertible preference shares under the shortfall facility of its recent Non-Renounceable pro-rata Entitlement Offer.

Funds will be used to progress the next phase of commercialization of BioDiem’s influenza vaccine (LAIV) licensing business; and its antimicrobial, BDM-I, in development for the treatment of infectious diseases through BioDiem’s subsidiary, Opal Biosciences Limited (“Opal Biosciences”).

ABOUT BIODIEM 

With rising concern about viral infections, “superbugs” and antibiotic resistance, BioDiem is well-positioned with its focus on commercialisation of infectious disease therapies and vaccines. An established ‘flu vaccine licencing business is drawing revenue from commercial partners in India and China. Nasovac-S™ is marketed in India and has recently received WHO prequalification which allows export to new markets.

New anti-infectives are needed due to increasing resistance to existing antibiotics, more difficult-to-treat infections, and paucity new treatments. BioDiem’s subsidiary, Opal Biosciences Ltd is an innovative player in infectious disease treatment, targeting human infection – a high growth, commercially attractive market segment.

To view the full announcement, please click on the button below.

Altech Chemicals Appoint Due Diligence Consultants

10th August 2016, ASX Announcement

Highlights:

  • Altech and KfW IPEX-Bank appoint lenders due diligence consultants
  • Technical, market and legal due diligence
  • Reputable international audit firm to provide “expert opinion” also mandated
  • Due diligence initiation meeting held in Stuttgart, Germany
  • Due diligence site visits at Meckering and Johor conducted last week

Altech Chemicals Limited (Altech/the Company) (ASX: ATC) is pleased to provide an important update on the progress of financing for its proposed high purity alumina (HPA) project.

Following the announcement 3 August 2016, of a positive pre-assessment by the German Government inter-ministerial committee (IMC) and Euler Hermes Aktiengesellschaft (Euler Hermes) of Altech’s export credit project finance application (refer ASX Announcement dated 3 August 2016 for details), due diligence consultants have now been appointed.

To view the full announcement, please click on the button below.

Powerhouse Ventures to Raise $21 Million From ASX Listing

3rd August 2016, Computerworld NZ, By Stuart Corner

Christchurch-based technology commercialisation company, Powerhouse Ventures, has lodged a prospectus with the Australian Stock Exchange for an IPO to raise up to $A20 million ($21m), after earlier flagging its intention to list on the NZX.

Chairman Kerry McDonald said the company would look to expand its operations into Australia. “We propose to enter the Australian market at a time when governments are determined to ensure university research funding generates commercial outcomes. Powerhouse intends to be a central part of this environment with its excellent university engagement model, business building expertise, capital and networks.”

McDonald said the offer would give investors the opportunity to invest in a business that will “identify and transform intellectual property from New Zealand and Australian universities into globally successful businesses.”

To view the full article, please click on the button below.

Folkestone Education Trust Results FY16: Profit of $106.8 million, an Increase of 20.5%

Folkestone Investment Management Limited as Responsible Entity of the Folkestone Education Trust (“FET” or the “Trust”) provides the results of the Trust for the year ended 30 June 2016.

Key Highlights
  • Statutory profit of $106.8 million, an increase of 20.5% from $88.6 million in the previous corresponding period (“pcp”)
  • Distributable income of $34.5 million, an increase of 16.2% on pcp
  • Distribution of 13.4 cents per unit (“cpu”), an increase of 4.7% on pcp
  • NTA per unit of $2.14, an increase of 17.6% from 30 June 2015
  • Total Unitholders’ return for the year to 30 June 2016 of 34.8%
  • New debt facilities were entered into with ANZ and HSBC resulting in the Trust having an average debt maturity of 4 years
  • Development pipeline of 18 centres with a total value of $103.4 million. Six development sites commenced operations during the year with a completion value of $26.3 million

An investor teleconference will be held at 2.30pm AEST today.  To register for the teleconference, please click on the link below.

For further information on FET’s results, please click on the links below.

US Residential Fund Patriot’s Pointe Syndication Live on Crowdfunding Platform

9th August 2016, ASX Announcement

US Residential Fund (ASX: USR “the Fund”) is pleased to announce that its first multifamily residential property syndication is now open to accredited investors through the online syndication platform CrowdStreet.

The property being syndicated, Patriot’s Pointe, is an A grade, 240-unit residential apartment complex set on 25 acres in North Carolina and purchased with attractive 30+ year fixed debt at 3.7% p.a. in place. Through the sydnication, USR is seeking to deliver investors:

Initial yield – 7.2%
Average 5-year yield – 8.1%
Total 5-year  IRR – 15-17%

The CrowdStreet platform’s main focus is investors that are US citizens. However, the Patriot’s Point syndication includes a structure that provides non-US investors the option of participating without having to file a tax return in the US.

To view the full announcement, please click on the button below.

Leaf Resources Investor Presentation August 2016

8th August 2016, ASX Announcement

Company Overview: Leaf Resource sis a green chemical company that uses plant waste/biomass to create industrial chemicals to replace petrochemicals in manufacturing.

  • Leaf’s Glycell™ process converts plant biomass into industrial sugars (a key component used to create green/sustainable chemicals)
  • Large cost advantage over other processes that create industrial sugars
  • Glycell™ is well-suited for a low-carbon world as it is sustainable, carbon friendly and cuts carbon emissions

The Problem: The world is actively shifting from petroleum based products

  • The high cost and environmental impact of burning finite resources has seen industry moving from the ‘black economy’ to the green economy.
  • Manufacturers are moving away from petrochem due to environmental concerns.
  • However, fossil-based petrochemicals are indispensable in our current society.

To view the full Presentation, please click on the button below.

Folkestone Seniors Living Fund No.1 Now Open for Investment

FSLF is well positioned for growth from the acquisition of Watermark Castle Cove, an award winning retirement living community on Sydney’s lower north shore, that is to be expanded (Initial Asset) and to acquire other high quality retirement living communities which may comprise both existing facilities and/or development opportunities in Sydney. Castle Cove is located approximately 12 kilometres north of the Sydney CBD.

The key investment highlights of the Fund include:

Exposure to Key Sector
- seniors living is a key and growing part of the economy
- ageing population is focusing on quality retirement accommodation

Strong Demographics
underpinned by ageing population
- positive demand for seniors living products

Attractive Returns

- targeting 15% IRR (pre-tax, post fees) over life of Fund

Experienced Partners
- partnering with key strategic developer/operators focusing on high quality, facilities with an excellent service culture

Quality Assets

- relatively new retirement living communities located in Sydney

Off Market Opportunity
- initial asset has been acquired off market via Folkestone’s network

The Final Close of the Offer will be the earlier of 9 September 2016 and the date when the total of the capital has been raised. The Fund has an expected term of 7.0 years.

AsiaPhos Reports Net Attributable Profit of S$0.4 million in 2Q2016

AsiaPhos Limited (“AsiaPhos” or the “Company”, and together with its subsidiaries, the “Group”), a Singapore-headquartered mineral resources company focused on exploring and mining phosphate with a vertically-integrated business model, reported its unaudited financial results for the second quarter ended 30 June 2016 (“2Q2016”).

In the quarter under review, the Group’s net attributable profit was S$0.4 million, compared to S$0.5 million in the corresponding period last year (“2Q2015”). Excluding non-cash charges of mainly depreciation and amortisation, the Group’s operating profit before working capital changes improved from S$1.2 million in 2Q2015 to S$2.0 million in 2Q2016.

Revenue for the Group was S$9.6 million in 2Q2016, against S$12.0 million in 2Q2015. The lower revenue was mainly due to the upstream operations which saw revenue decreasing from S$6.5 million in 2Q2015 to S$3.6 million in 2Q2016, as the Group retained the higher quality phosphate rocks for its in-house P4 production, and sold only the lower quality rocks AsiaPhos Limited: 2Q2016 Results Press Release which fetched lower average selling prices. In addition, the quantity of rocks sold in 2Q2016 was 57,600 tonnes, compared to 89,100 tonnes in 2Q2015.

On the other hand, revenue from downstream operations rose from S$5.5 million in 2Q2015 to S$6.0 million in 2Q2016, driven by the higher sales of P4 from 1,900 tonnes in 2Q2015 to 2,300 tonnes in 2Q2016.

In its continual efforts to improve prod production efficiency, by securing cheaper electricity costs and carrying out improvements to one of its furnaces, the Group had successfully reduced the production cost of P4 in 2Q2016. This led to an overall improvement in the Group’s gross profit margin to 20% in 2Q2016, from 17% in 2Q2015.

Commenting on the results, Dr Ong Hian Eng (王显荣博士), Chief Executive Officer of AsiaPhos Limited said,

“The mining season had resumed in March this year, and our mining output run-rate is showing a promising growth trend. We were able to achieve an average daily output of about 1,800 tonnes in 2Q2016, which far exceeds the average of 1,400 tonnes in FY2015. This is the direct result of our previous investments in improving our mining infrastructure, and we expect to increase our rock production in FY2016 which should contribute positively to the Group’s cash flows and profits.”

Outlook

For the remainder of the current financial year ending 31 December 2016 (“FY2016”), phosphate rock prices are expected to soften moderately. Meanwhile, in July 2016, the Sichuan Provincial People’s Government (四川省人民政府) announced that, with effect from 1 July 2016, the policy to collect a price adjustment levy and resource compensation fee amounting to RMB14 per tonne of phosphate rock will be abolished. At the same time, the resource tax will be computed based on 8% of the selling price of the phosphate rocks, instead of a fixed RMB15 per tonne of phosphate rock. Based on the current available information, the Group expects that the above changes will lead to a reduction in production cost of the phosphate rocks in the second half of FY2016.

The price outlook for P4 is expected to remain challenging. Though the Group anticipates production cost for P4 to be lower in FY2016 than the previous year, it will continue to monitor the situation and take steps to ensure the economic production and profitability of P4. The Group will continue to diversify revenue contribution from the downstream business segment by exploring the export market for P4 and other downstream phosphate-based chemical products.

Corporate Updates

In July 2016, the Group received the renewed exploration rights for the Fengtai Mine and Mine 2, with the renewed rights being valid till December 2017 and June 2018 respectively.

Earlier this year, the Group had submitted an application to the Sichuan Land Department (“Authority”) to convert the Mine 1 exploration license into a mining license so that the approved annual production scale for Mine 1 can be increased from 50,000 tonnes to potentially 400,000 tonnes. The application is currently pending approval by the Authority.

YPB Protects Retailer Dan Murphy’s Against Theft

5th August 2016, ASX Announcement

Highlights:

  • YPB’s Lexcaps used as anti-theft deterrent across Dan Murphy’s retail outlets
  • Estimated that Dan Murphy’s will use more than 100,00 units per annum

Brand Protection and Customer Engagement solutions company YPB Group Limited [ASX: YPB] today announced that its proprietary anti-theft Lexcaps will be used across Dan Murphy’s stores Australia wide.

YPB’s Lexcaps are reusable security caps that are applied to bottle caps and removed by service staff at the point of sale. A person attempting to steal a bottle with a Lexcap will trigger an alarm at the exit.

In successful trials with the liquor industry and Dan Murphy’s in particular, theft was reduced significantly on YPB protected liquor bottles.

To view the full announcement, please click on the button below.

YuuZoo FY16 Update: Signs Agreement with Etisalat, for Launch of Powerful New E-Commerce Platform Targeting SMEs

YuuZoo together with Etisalat, the largest mobile operator in Africa and the Middle East, will launch a powerful new e-commerce platform targeting the country’s SME market. “SME Arena” (www.smearena.com.ng) which is built and managed by YuuZoo and marketed in Nigeria by Etisalat, helps SMEs to market and sell their products and services. Users of SME Arena can also enjoy the tribal social networks and games offered on the platform.  This agreement has unlocked immediate access for YuuZoo to an additional of 24 million Nigerian subscribers while targeting Nigeria’s entire 180 million population.

ABOUT YUZOO

Listed on the SGX mainboard (SGX: AFC), with access to over 45 million registered users, 700 million TV viewers and 100 million followers in 164 countries, YuuZoo has created a globally unique and profitable new business model in social media.

Social networking, e-commerce and gaming is offered to consumers in a mobile-optimized virtual shopping mall, where they can access hundreds of targeted social networks, shops and entertainment through one single login. The company grows internationally through a profitable franchise model. All networks are localized for each market in language, merchandise and design.

Prescient Therapeutics Granted USPTO Allowances for Two PTX-200 Patents

4th August 2016, ASX Announcement

Clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) is pleased that the US Patent and Trademark Office (USPTO) has issued two notices of allowance under the PTX-200 patent families “Effective treatment of tumors and cancer with triciribine and related compounds” and “Compositions including triciribines and taxanes and methods of use thereof“.

The first allowance bears relevance to claims involving the intravenous dosing schedule of novel Akt inhibitor, PTX-200, including a method for identifying and treating patients with tumors in the pancreas, ovary or colon that have highly expressed Akt.

The second allowance has allowed claims bearing particular relevance to PTX’s ongoing breast cancer clinical trial, involving the use of PTX-200 with taxanes.

To view the full announcement, please click on the button below.

DomaCom’s IPO Goes Live 31st August – Offer Closing Soon!

DomaCom lodged its Prospectus with ASIC on the 24th July and is planning to IPO on the ASX on the 31st August. The Offer is currently open and investors can participate for as little as $2,250. Below is an update on the most recent events and media for DomaCom.

ABOUT DOMACOM

DomaCom Ltd is the first and only regulated fractional property platform in the country. Following a 5-year development and launch phase which has seen the company acquire 16 properties and initiate another 37 bookbuilds, DomaCom is taking the next major step in its corporate journey with a listing on the ASX. DomaCom is seeking to raise $10 million in the IPO, with $5 million already underwritten.

 

Altech Positive Pre-Assessment German Export Credit Finance

3rd August 2016, ASX Announcement

Highlights

  • Positive pre-assessment by German inter-ministerial committee
  • Important milestone in the assessment process of Altech’s ECA application
  •  Formal detailed due dilligance of the project to commence

Altech Chemicals Limited (Altech/the Company) (ASX: ATC) is pleased to report that it has been officially advised by Euler Hermes Aktiengesellschaft (Hermes), the German Export Credit Agency (ECA), of a positive pre-assessment by the German Government inter-ministerial committee (IMC) and Hermes, of Altech’s export credit project finance application for cursory review (refer ASX Announcement dated 22 March 2016 for details).

The positive pre-assessment of Altecch’s export credit application is an important milestone in the assessment process of the Company’s high purity alumina (HPA) project and its  ECA application.

To view the full announcement, please click on the button below.

PeriCoach Granted Patent Protection in China

3rd August 2016, ASX Announcement

Analytica Ltd (ASX: ATL), manufacturer of the PeriCoach® System has been granted patent protection (Patent No ZL201280018210.2) in the People’s Republic of China for the device’s unique pelvic floor sensing technology. It is estimated that there are nearly 227 million target women with urinary incontinence in China. This is the first of the PeriCoach patents to be granted in the major markets and is in line with the overall strategy for PeriCoach: to secure intellectual property protection for key geographies that have ageing populations, with increased awareness of urinary incontinence, and growing demand towards conservative treat solutions.

It has remained a top priority to ensure the PeriCoach becomes a global product, therefore Analytica has maintained its investment on intellectual protection in major markets around the world.

To view the full announcement, please click on the button below.

Folkestone Education Trust: Investor Teleconference FY16 Results

Folkestone Investment Management Limited as Responsible Entity of the Folkestone Education Trust (“FET” or the “Trust”) will be announcing its financial results for the year ended 30 June 2016 on Tuesday 9 August 2016.

After release of the results, the Trust intends holding an investor teleconference on Tuesday 9 August 2016. Management invites investors to participate in this teleconference in which the Trust’s FY16 results and presentation will be discussed. There will be an opportunity for participants to ask questions at the end of the teleconference.

To register for the teleconference please follow the registration details below.

Meeting: Folkestone Education Trust FY16 Results to 30 June 2016
Date: Tuesday 9 August 2016
Start time: 2:30 PM AEST
Duration: 30 minutes plus questions
Register attendance: To register your attendance please click on the Register Here button below.

Once you have registered, you will be provided with the information you need to join the conference, including dial-in numbers and a passcode.

If you need assistance while on the teleconference, press *0 on your telephone, and an operator will be happy to assist you.

To register, please click on the button below.

Block Viewers Can Crowd Fund Their Favourite Apartment with DomaCom

1st August 2016, Property Observer

Viewers of The Block now have the opportunity to join a crowdfunding campaign to buy one of the five apartments in the upcoming Port Melbourne series.

The 12th season of The Block starts shortly on Channel 9 with five couples.

This time viewers can be actively involved as an investor for $2,500 through crowdfunder DomaCom as the DomaCom CEO Arthur Naoumidis is a fan of Australia’s longest running reality show.

“I have always been a great fan of The Block, and allowing viewers the opportunity to actually invest in one of the apartments will bring another dimension to this acclaimed program,” he said.

“Viewers will be able to use DomaCom’s platform as an investment vehicle in one or more of the apartments, effectively vastly widening the net of those viewers who can be involved at this level.”

To view the full article, please click on the button below.

OncoSil Medical Receives IDE Approval from the U.S. FDA

2nd August 2016, ASX Announcement

OncoSil Medical Limited  (ASX: OSL) (OncoSil Medical or the Company) a late stage medical devices company focused on localised treatments for subjects with pancreatic and liver cancer, is pleased to announce that it has recieved Invesigarional Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA). The Company will now initiate a pivotal clinical investigation for OncoSil™ for the treatment of eligible subjects with pancreatic cancer.

OncoPac-1 U.S. and International Clinical Study 

As previously advised, the Company had filed an IDE Amendment with the FDA for its planned global clinical study of OncoSil™ for the treatment of pancreatic cancer (OncoPac-1). This followed an intensive eight month process of submissions and interactions with the FDA.

The Company has received notification from the FDA that the IDE Amendment submission has been approved thereby clearing the way for the Company to initiate its planned global clinical study, OncoPac-1

To view the full announcement, please click on the button below.

Martin Jetpack Business Status Update: Status of the Series 1 Aircraft, Commercialistion & Certification

2nd August 2016, ASX Announcement

Martin Aircraft Company (Martin Aircraft or Company) makes the following announcements:

  • Update on the Status of the Series 1 aircraft
  • Commercialistion Update
  • Certification Update

Update on the Status of the Series 1 Aircraft 

The Company’s existing principal focus is on completing the Series 1 Martin Jetpack assembly by the end of 2016 with the aim of flight testing, demonstrating ad delivering the Series 1 aircraft in early 2017. Potential customers have indicated that repeated demostrartions of the Jetpoack will provide the confidence necessary to lead to those customers placing orders. Other customers have indicated a desire for such early aircraft to conduct trials.

To view the full announcement, please click on the button below.

BPS Expands in USA

2nd August 2016, ASX Announcement

Highlight:

  • BPS continues to execute its Bartercard growth strategy in North America, opening new franchises in New Hampshire, Alabama and Georgia, with at least four more US franchises in the pipeline

Leading finaicial technology platform provider BPS Technology Limited (ASX: BPS, “the Company”) is pleased to announce that it has continued to expand the reach of its Bartercard operations in North America.

BPS has three new Bartercard franchises in Mobile (Alabama), Portmouth (New Hampshire) and Savannah (Georgia).

The new franchises bring the Company’s number of representative territories in North America to 12. This is consistent with Bartercard’s stated plans of expanding across the country by opening franchises in key strategic areas.

To view the full announcement, please click on the button below.

Nevhouse FY16 Update: $1M Raised & Further $2M Expected, Won Sustainability & Architecture Awards, New Investors

Nevhouse –www.nevhouse.com - an Australian sustainable social enterprise, has raised A$1M to date and expects to secure the remaining A$2M by the end of Q3 2016. This follows the successful completion of our initial sustainable community development project in Vanuatu and winning both the Sustainability and Architecture awards at the 2016 Australian Good Design Awards. Our story and innovative design approach to flat-pack housing were also broadcast on ABC’s 730 Report:

http://www.abc.net.au/news/2016-04-19/nev-houses-surfboard-designer-flat-pack-cyclone-proof-housing/7335324

Our design capabilities have also been further enhanced by Brookfield Multiplex – who have offered Nevhouse access to their skills, IP and experience in sustainable housing. This is an exciting development for our business and underpins our innovation agenda and ensures we remain ahead of our competitors.

Recent new investors include Gary Flowers (former CEO at Australian Rugby and former COO at the Mirvac Group) – who along with Grant Mason (formerly Elanor Investors group) have both agreed to act as Strategic Advisers to the business.

The sales pipeline has also grown significantly with many opportunities to help people living in Australia, Fiji, Sri Lanka, PNG and Vanuatu – all of which are expected to close in 2016.

Management are therefore confident we will achieve our sales and profit targets by the end of 2016 – which sets Nevhouse up for an even stronger growth year in 2017.

 ABOUT NEVHOUSE 

Nevhouse is a philanthrocapitalist organisation – founded by Australian surfing icon, Nev Hyman – that believes in “Doing Well by Doing Good”. The business is seeking US$5 million+ in new capital to roll out ‘sustainable community development’ projects in Vanuatu and Papua New Guinea. The houses and other structures were designed by Ken McBryde from Hassell Architects – a leading global specialist in indigenous housing.

We believe Nevhouse is unique compared with traditional “bricks and mortar” options – which are more costly, not sustainable and take 3-4 times longer to build. Demand for affordable housing is strong in most parts of the developing world and our focus in 2016 is in the Pacific which will provide a platform for global growth in 2017 and beyond.

Alcidion to Meet with NSW Health Minister

2nd August 2016, ASX Announcement

New South wales Governemnt Policy requires certain details of meetings held with the Minister to be publicly disclosed ona quarterly basis. The policy (Publication of Ministerial Diaries) is available at www.dpc.nsw.gov.au

In accordance with the Company’s continuous disclosure requirements and NSW Government Policy, we wish to advise the market of the following details:

Proposed Date of meeting: Thursday 4th August 2016

Attendees: Hon. Jillian Skinner MP, Minister for Health; Mr Ray Blight, CEO Alcidion Group; Mr Nathan Buzza, Executive Director Alcidion Group

Purpose and topic of meeting: NSW eHealth Strategy

To view the full announcement, please click on the button below.

Martin Jetpack Company Shareholder Newsletter August 2016: Test Rigs Proving a Success, Bubba Watson, Oakley and the Martin Jetpack

1st August 2016, ASX Announcement

This month we talk about the success we’re having with our three test rigs. We also introduce you to our Head of Aircrew and Flight Testing, give an update on our attendance at the Airborne Law Enforcement Association Expo and Bubba’s Jepack.

  • Test Rigs Proving a Success
  • Meet Chief Test Pilot Prospero Uybarreta
  • P14 and Production Readines
  • Airborne Law Enforcement Association Expo
  • Bubba Watson, Oakley and the Martin Jetpack

To view the full Newsletter, please click on the button below.

Catcha Group Partner Update August 2016: Patrick Grove Joins World-Class XPrize Innovation Board, iflix Aims for International Expansion

APAC Leading Entrepreneur Patrick Grove Joins World-Class XPrize Innovation Board 

e27 
Patrick joins a world-class Foundation whose Trustees includes luminaries such as Elon Musk, James Cameron, and more
Read more

Southeast Asian Startups Beat Netflix At Its Own Game

Bloomberg View
In January, Netflix launched its service in more than 130 new countries, promising to become a “global TV network”. So far, however, audiences aren’t as interested as the company hoped. According to a statement issued last week, international subscribers grew at the slowest rate since 2014, when Netflix was available to far fewer people.
Read more

iflix aims for international expansion with 3 senior appointments
e27 · Read More

iflix set to expand beyond Southeast Asia
Malay Mail Online · Read More

Australia: Frontier Digital Ventures to raise $18.7m in ASX IPO
Deal Street Asia · Read More

Digerati50 turning broadcast TV on its head
Digital News Asia · Read More

iflix scores exclusive on Mr Robot for Southeast Asia
World Screen · Read More

More Catcha Group coverage here

 

YPB Enters Retail Anti-Theft Business

1st August 2016, ASX Announcement

Anti-counterfeiting and consumer engagement technology company YPB Group Limited (ASX:YPB)  is extending its PROTECT solutions suite into anti-theft applications, initially targeting major Australian retail chains. This broadening of YPB’s PROTECT, DETECT, CONNECT brand protection offering is expected to create a meaningful new source of recurring revenue for the company.

Using its existing capabilities and technolgies, YPB is able to deleiver several highly effective anti-theft solutions including RF (radio frequency) and AM (acousto-magnetic) pricing and product label, integrated tags and lanyards, self-alarming tags and other tailored options. One of the company’s propriety solutions of great interest to Australian mainstream retaileers is the ‘Lexcap’, which provides in-store protection for high end wines and alcohol.

To view the full announcement, please click on the button below.

Crowd Mobile Expands Into China With SmartTrans Partnership

1st August 2016, ASX Announcement

Highlights

  • Crowd Mobile signs Letter of Intent with SmartTrans to utilise SmartTrans’ proven and established payments platform in China
  • Crowd Mobile will leverage SmartTrans’ payments platform to launch product offering and quickly and easily monetise in the Chinese market
  • Crowd Mobile will gain access to over 1 billion potential customers across the SmartTrans network
  • Crowd Mobil’es successful Q&A products have been localised for the Chinese market
  • China is the world’s laregst e-commerce market, estimated to top US$1.1 trillion by 2020 according to Forrester

Crowd Mobile Limited (ASX: CM8 & FWB-XETRA: CM3, Crowd Mobile, “the Company”) is pleased to announce it has signed a Letter of Intent (LOI) with SmartTrans Holdings Limited (ASX:SMA) and its subsidiary SmartTrans Technology (Beijing) to form a partnership that will give the Crowd Mobile an effective entry point to the Chinese market.

To view the full announcement, please click on the button below.

Tesserent Quarterly Report June 2016: Blue Reef Acquired Successfully, On Track to Deliver New Technology, Cash Position at $3.45m

29th July 2016, ASX Announcement

Tesserent Limited (ASX: TNT) had a productive quarter, successfully completing the acquisition of the Blue Reef business, recruiting two new members to the Tesserent Executive team and continuing to grow the business with an expanding customer base.

Key highlights during the quarter 

  • Successful completion and integration of the Blue Reef business acquisition funded with a combination of cash and equity consisting of $1.0 million in cash ($500,00 paid on completion, with two subsequent payments of $250,00 to be paid in November 2016 and May 2017), 12,875,00 ordinary fully paid shares and sundry acquisition costs. The assets acquired from this transaction are a key element to Tesserent’s strategy within the Education sector to provide a specialised security and cyber safety offering to schools. Moving forward, this part of the business will go to market under the Tesserent Education brand.
  • Tesserent continues to place an emphasis on the development of our won technology, enabling us to offer our proprietary services to our customers. Tesserent’s development team, headed-up by Nick Conolly, continues to drive our R&D programs ad is on track to deliver new technology releases as scheduled in our prospectus.

To view the full announcement, please click on the button below.

Alcidion Group Quarterly Report: Successful Reverse Takeover of Naracoota Resources, Commercialiation Strategy Commenced

29th July 2016, ASX Announcement

Executive Summary

Alcidion’s first quarter following the successful reverse takeover of Naracoota Resources Limited marked the commencement of the Company’s commercialisation strategy of its Miya platform.

As at 29th July 2016 the Company maintains $6.51 million in available cash, this amount excludes the provision for an estimated Research & Development Tax Incentive of $997k.

During FY16, the Company continued its committment to Product Development, having invested $2.20m in Research & Development, principally focussing on the development of its highly anticipated Computerized Physician Order Entry (CPOE) platform and the deployment of this technology at our luminary site in the Northern Territory.

The Company commenced its commercialiation strategy, which in broad terms adopts an engagement strategy that will see the Alcidion Sales Team systematically engage the continuum of Australian and New Zealand healthcare organisations, whilst simultaneously seeking Value Added Resellers and Strategic Partnerships.

The healthcare industry has realized that the traditional approaches to patient flow management and cost management are inadequate to keep pace with the emerging challenges. Therefore, patient flow management solutions will be among the priorities on the investment list of healthcare organizations for highly streamlined patient flow outcomes and cost management.

Completion of the Reverse Takeover of Naracoota Resources

On 29 February 2016, the Company completed the Reverse Takeover of Naracoota Resources (ASX:NRR).  Both Naracoota Resources Limited and Alcidion Corporation Pty Ltd incurred substantial one-off legal, accounting, corporate advisory and compliance expenses leading up to and post Reverse Takeover, which resulted in an estimated $550k of outbound cash flows in FY16. The prospectus detailed an estimated $400k of expenditure on behalf of Naracoota Resources for the Reverse Takeover and Alcidion Corporation Pty Ltd incurred $150k of expenditure directly related to the transaction.

To view the full announcement, please click on the button below.

Altech Chemicals Quarterly Activities Report: New Cornerstone Investor, EL Sold for $2 million, Meckering Mining Lease Grant

29th July 2016 , ASX Announcement

Highlights

Altech secures another quality cornerstone investor 

  • Altech secures Malaysian publicly listed MAA Group Berhad (MAAG) as cornerstone investor
  • MAAG is an insurance, investment, creidt and finance group with total asset of RM1.45 billion
  • Placement of $1.0 million of March 2016 shortfall shares

Meckering mining lease grant 

  • Meckering mining lease M70/1334 granted on 19 May 2016
  • 250+ years kaolin feedstock for 4,000tpa Malaysian HPA plant

Altech sells EL for $2 million cash 

  • Dana legal action resolved
  • Sale of surplus exploration licnece for $2 million
  • Altech retains 1–% ownership of ML (M70/1334)

Update to kaolin resource for mining lease 

  • JORC 2012 kaolin resource estimiated for mining lease M70/1334
  • Indicated Mineral Resource of 11Mt of kaolin @ 82.7% ISO brightness
  • Sufficient to support high purity alumina plany for >250 years mine life at 4,000tpa production

To view the full announcement, please click on the button below.

Aeeris FY16 Update: Continues Rapid Development of Business, Products, and Revenue Growth

Aeeris continues its evolution towards a demand-driven, highly scalable annuity revenue business based around diversified enterprise-levelgeospatial data technologies and services.

New customers for severe weather data include NBNCo, SEQWater, Melbourne Water, and all the major insurance companies except IAG.

Also, we have trials ongoing with a shopping centre major and a casino operator of our new “SecureAMS” products which track and monitor personnel, and automate key access to security areas within large premises.  This product has global potential which Aeeris is exploring.

Aeeris is also looking at several potential acquisition opportunities.

ABOUT AEERIS

Aeeris is focused on providing enterprise and government customers with intelligence which enable them to manage and protect assets, operational risks and human resources.

The Company’s Early Warning Network system and proprietary GNIS technology platform ingests vast amounts of live data from multiple sources on severe weather, fire, traffic, grid, natural and other hazards, and sends alerts and data to customers who need this information, enabling decision superiority.

The platform and related apps allow tracking, mapping and monitoring of large numbers of users, communicating instantly with them about events which impact their operations, safety, security and productivity.

Leaf Resources Quarter Update June 2016: Expecting to Receive $510,000 from R & D Tax Rebate

29th July 2016, ASX Announcement

Attached to this update are the current quarterly cash report (Appendix 4C) for the quarter ended 30th June 2016.

As previously announced the company  is expecting to receive $510,000 from the R & D Tax Rebate in the near future. Previously announced returns from the EMDG and Research fees have been received.

ABOUT LEAF RESOURCES  

Strong Technology: Simple, innovative process with IP protected.
Opens New Markets: Facilitates conversion of abundant waste biomass to rapidly emerging biofuels, bioplastics and green chemical markets
Rapid path to market: Technology has the characteristics needed to successfully go to market as planned in 2014.
Environmental Credentials: Technology capitalises on switch to green economy, using waste materials. Facilitates large carbon savings in multiple markets.
Strong Value Proposition: Low Capex/low Opex/low energy solution for end users.
Scaleable Business Model: Technology licensing to national and international territories into multiple markets.
Big Opportunity at Low Value: seeking $800,000 through rights issue at $0.035 which values company at less than $1.65m.

To view the full announcement, please click on the button below.

Alcidion FY16 Update: Public Listing, $2.35m MoU with Western Health, $2.20m to Research & Development

Alcidion Group Limited (ASX: ALC), an innovative health informatics company, has had an exciting past 12 months following its public listing on 29th February 2016.

The healthcare industry has realized that the traditional approaches to patient flow are inadequate to keep pace with the emerging challenges. Therefore, patient flow management solutions will be among the priorities on the investment list of healthcare organizations for highly streamlined patient flow outcomes and cost management.

The company executed a $2.35m MoU with Western Health marking the commencement of its commercialization strategy, for its range of award winning software solutions.

During FY16, the Company committment $2.20m to Research & Development, principally focussing on the development of its highly anticipated Computerized Physician Order Entry platform and the deployment of this technology at our luminary site in the Northern Territory.

ABOUT ALCIDION GROUP 

Alcidion is the brainchild of the former CEO of the SA Heath Department and Professor Malcolm Pradhan, a Stanford qualified physician. Over the past decade, Alcidion has invested $15m into the R&D of the cutting edge Clinical Decision Support System and is now focussed on commercializing the technology.

The introduction of Patient Protection & Affordable Care Act 2010 (“Obamacare”) requires US hospitals to accelerate the adoption of Electronic Medical Records.  Alcidion is a leading supplier of these systems in Australia and is now seeking to expand its operations into the United States.

The company is backed by Allure Capital, the private investment vehicle of technology entrepreneur Mr. Nathan Buzza and BlueSky Private Equity (ASX:BLA).  Mr Buzza was previously the second largest shareholder of Clinical Middleware Provider, Azure Healthcare (ASX:AZV), which catapulted into the spotlight after the stock rocketed from 3.3c to 34c over his two and a half year tenure.

Dimerix FY16 Update: Significant Progress on its DMX-200 Program, FDA Confirmation, Trial Recruiting Well

Dimerix has made significant progress on its DMX-200 program for chronic kidney disease.

Dimerix met with the US Food and Drug Administration (FDA) discussing DMX-200 development for Focal Segmental Glomerularsclerosis (FSGS). Dimerix confirmed the DMX-200 regulatory path as an adjunct therapy, not a combination therapy, reducing complexity and costs of trials.

Proteinuria is a risk factor for disease progression in FSGS patients. The FDA confirmed reduction of proteinuria could be devised as a primary end point for registration.

The DMX-200 Phase II trial is recruiting well. Dimerix intends to provide an interim data analysis during Q3 of 2016.

ABOUT DIMERIX

Dimerix is a clinical stage Australian Biotechnology company developing and commercialising novel drug therapies targeted at unmet patient needs, with the lead phase II clinical program (DMX-200) targeting chronic kidney disease (CKD).

The DMX-200 clinical trial is currently recruiting patients with proteinuria, with an interim read out expected in mid 2016. DMX-200 has also received Orphan Designation from the FDA for the treatment of one cause of CKD, Focal Segmental Glomerularsclerosis (FSGS).

The therapeutic rationale for DMX-200 was developed from Dimerix’s core patented technology, Receptor – Heteromer Identification Technology (Receptor – HIT), which can be used to elucidate receptor interactions. Applying this knowledge to drug targets has enabled Dimerix to identify combinations of receptors, which if targeted together, could result in greater efficacy or fewer side effects than traditional approaches.

Dimerix has also assisted several top 10 Pharmaceutical companies with their drug discovery programs by applying the HIT technology. These studies provide validation of Dimerix’s in vitro rationale for pursuing in vivo therapeutic studies.

ThinCats Australia Joins Forces with Leading Property Crowdfunder DomaCom

Investment platform operator DomaCom and SME peer-to-peer lender ThinCats will collaborate to provide greater scope for exposure to property and loan opportunities.

In its announcement on Friday, DomaCom – soon to be listed as a crowdfunding service – said Australia’s peer-to-peer business lending sector had benefited from the tightening of bank lending to small to medium size enterprises (SMEs).

“Our link with ThinCats will give advisers the ability to sit on both sides of a property transaction by creating leveraged book builds,” said DomaCom chief executive Arthur Naoumidis.

“This also provides the 350 lenders on the ThinCats platform the opportunity to gain exposure to property assets and the ability to lend funds at an attractive interest rate with a lower risk profile.”

He added that when targeting growth instead of income, advisers using DomaCom would have to include debt in some book builds.

Echoing the sentiment about opportunity, ThinCats chief executive Sunil Aranha said that the link with DomaCom would “allow our lenders to gain exposure to both property and new loan opportunities”.

“Lenders on our platform are now providing more than $1 million in loans per month and DomaCom will lift our lending volumes even further,” Aranha said.

Loans would be lower risk and would have to be positively geared, Naoumidis said, with an initial loan to value ratio of no more than 50 per cent.

“The default rate for the fund borrowing the money is a low 3.5 per cent above the ANZ overnight cash rate – this currently equates to 5.25 per cent per annum,” he said.

“As the cost of the facility is 0.5 per cent of the loan amount, lenders will currently receive 4.75 per cent per annum – an attractive return in this low rate environment.”

He said investors were seeking a good yield without going too far up the risk curve, meaning there would likely be strong interest in the new facility.

“This is a wonderful illustration of true disruption, with a crowd funding platform and peer-to-peer lending platform working together to enable [self-managed superannuation funds] to benefit from gains associated with property ownership whilst earning attractive fixed income returns,” Aranha added.

Alcidion (ASX:ALC) Sign $2.35m MoU with Western Health

Executive Summary:

  • $2.35m MoU for Footscray, Williamstown & Sunshine Hospitals.
  • Initial Term of three years, with an option to extend for an additional two years.
  • Apple iPad’s view Electronic Patient Records and highlight emerging clinical risk.
  • Optimises Patient Flow, Bed Management across the hospital group.
  • Patient Flow Market set to grow from $USD251m to $USD678.4 Million by 2019.

Western Health has signed a $2.35m Memorandum of Understanding with Alcidion Group Limited (ASX:ALC) to utilise the company’s technology across its three facilities. Western Health employs 6,500 staff and manages three acute public hospitals: Western Hospital at Footscray; Sunshine Hospital at St Albans; and the Williamstown Hospital.

The Miya platform provides all the necessary data to best manage patient care, from the Emergency Department through to the hospital wards. Clinicians can access individual patient information on a myriad of mobile devices and view clinical information such as pathology and radiology results as well as access clinical documentation. Furthermore, the platform identifies emerging clinical risk and highlights at risk patients to the clinicians using the system.

In the Emergency Department, clinical staff can quickly identify those patients nearing the National Emergency Access Target (NEAT) and plan care accordingly. The solution provides an overview of capacity and demand at both the ward and unit level, providing real time information about open and available beds, patients coming in (together with the admission source) and potential and confirmed ward discharges.

CEO of Alcidion Group Limited, Mr Ray Blight commented, “We are delighted to see Western Health extend the relationship with Alcidion.  Western Health should be commended on their commitment to excellence in innovation and Alcidion is privileged to be work closely on these ground breaking initiatives”.

“Efficiency improvements are by far the most significant driver for investments in patient flow solutions.  More specifically, healthcare organisations are focused on improving bed turnaround times and reducing patient wait times.  We are delighted to be working with Alcidion in this cutting edge Patient Flow Solution”, Executive Director of Operations, Western Health, Russell Harrison said in a statement.

According to leading market research firm, Markets and Markets, the global patient flow management solutions market is estimated to grow at a CAGR of 22% from 2014 to 2019, to reach $678.4 million by 2019 from $251 million in 2014.

Over the years, the healthcare industry has realized that the traditional approaches to patient flow management and cost management are inefficient to keep pace with the emerging challenges. Therefore, patient flow management solutions will be among the priorities on the investment list of healthcare organizations for highly streamlined patient flow outcomes and cost management.

The total contract value requires Western Health Board approval.

Medikane FY16 Update: $500,000 Raised, Share Price Increased 22%, Appointing Distributors in India, Thailand, Sri Lanka, and Oman

MediKane raised $500,000 recently which increased the share price by 22%.

Ex Hardie Exec VP Peter Baker joined the Board and Michael Goldman ex Diabetes Australia joined as Senior VP USA posted in New York.

The business is appointing distributors in India, Thailand, Sri Lanka, and Oman.

MediKane’s diabetes treatment NutriKane D appeared in the health segment on channel 7 News late 2015 and a constipation product, NutriKane + was just launched.

A clinical trial is being undertaken at Royal Melbourne Hospital to demonstrate that NutriKane D (diabetes product) lowers blood glucose levels. Results will be published in mid-2017.

ABOUT MEDIKANE

MediKane sells natural medical products for specific health conditions. Clinical trials performed by the Royal Melbourne Hospital demonstrated the efficacy of the product for treatment of gut health and recent trials by diabetes organisations have demonstrated its ability to modulate blood glucose levels. The product branded NutriKane, is registered as a food not a pharmaceutical. The sales launch was in November using five channels including hospitals, diabetes organisations and distributors direct to Health Care Professionals.
Gross Margins vary from 45 to 70 % depending on channel.

MediKane is raising funds for further market penetration and for trials to extend the product evidence base. The business will be cash positive within 6 months, or sooner with investor funds.

SUDA Quarter Update June 2016: Cash Position at $2.4 million

29th July 201

SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the fourth quarter of FY2016. Receipts from customers for the period were $1.5 million, an increase of 12% from the fourth quarter of FY2015.

The net operating cash loss for the fourth quarter was $1.0 million, compared to $0.7 million in the same period of the previous year. The increase in cash outflow in the quarter included an adjustment for research relating to SUDA’s new-generation optimised SUD-003 sildenafil oro-mucosal spray for erectile dysfunction. There was also an increase in payments for other working capital. The cash position as at 30 June 2016 was $2.4 million.

SUDA’s CEO, Mr Stephen Carter, commented: “Our negotiations with pharmaceutical companies to license SUDA’s first-in-class oro-mucosal sprays continue to advance towards final agreements. These discussions span various products and territories. We have overcome several product-related challenges that have slowed the pace of licensing discussions. With these matters addressed, we are well placed to finalise multiple commercial agreements. In addition, our medical and surgical supplies subsidiary, Westcoast, continues to perform well

YPB Company Update July 2016: MOU with Orora Ltd, India Launch, Mexican Vital Government Documents

29th July 2016, ASX Announcement

YPB Group Limited (ASX:YPB) is pleased to provide a summary of activities for the quarter ended 30 June 2016.

The quarter saw further progress in the commercialisation of YPB’s unique suite of technologies with key achievements including:

  • Singing a binding MOU with Orora Ltd, a global packaging solution provider to the food and beverage industries, to provide YPB’s full suite of technologies to Orora’s customers. The MOU will advance to a supply agreement which is currently in final documentation stage.
  • Through the Affrymx joint venture focusing on Mexican Vital Government Documents, YPB has now secured four contracts for the supply of vital records in Mexico. The most recent order, for 395,000 viral record documents, was placed by one of Mexico’s most populous states and represents a key milestone for YPB as it aggressively pursuers the vital record business for Mexico’s 120 million citizens.
  • A new customer in Southeast Asia secured for the VariSec ePassport technology, with an existing customer placing a 14 million unit re-order. YPB Varisec is now supplied to 18 million of the 125 million e-passports issued annually.
  • Launch of YPB in India after a Joint Venture with cricket legend Sachin Tendulkar’s team was signed as part of a ten year agreement.

To view the full announcement, please click on the button below.

MedAdvisor Quarterly Report June 2016: Strong Operational Performance, Cash Receipts Totals $292k, Pharmacy Network and Number of Patients Increases

29th July 2016, ASX Announcement

Highlights

  • Strong operational performance with an increase across all key revenue drivers
    - Over 180,000 patients using the platform as at 30 June 2016, a 132% increase on the prior corresponding period
    -  Expansion of pharmacy network by 33% on the prior corresponding period to over 1,600 pharmacies, encompassing over 30% of all Australian community pharmacies
    - Key partnerships with pharmaceutical manufacturers for Patient Engagement Programs (PEP)
  • Cash receipts for the quarter totalled $292k, an increase of 7% on the previous March 2016 quarter
  • Tap-To-Refill script ordering function continues to perform, becoming a key drover of patient engagement, with 40% of the user base currently utilising the function
  •  MedAdvisor continues to expand its pharmacy network and increase the number of patients on the platform , driving transactional and subscription revenue

MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication management company, has today released its Appendix 4C Report for the three-month period to 30 June 2016 and is pleased to provide a review of the progress during the period.

To view the full announcement, please click on the button below.

iFAST Corp Continues Towards Achieving Long-Term Vision of Integrated Investment Products Distribution Platform

29th July 2016, iFAST Corporation

  •  The Group communicated that it continued to make progress towards achieving its long-term vision of being an integrated investment products distribution platform, which is key to robust growth rates in the medium to long term in Asia’s wealth management industry
  • In the short term, however, adverse equity market conditions affected the Group’s financial performance. With Asia ex-Japan markets hitting 5-year lows in the first half of this year, the Group’s net revenue (excluding China) declined 10.6% YoY in 1H2016
  • Expenses for the Group (excluding China) increased 7.0% YoY in 1H2016, reflecting the Group’s continued push towards broadening the range and depth of our products and services
  • The combined impact of a decline in net revenue and an increase in expenses resulted in a 40.5% decline in the Group’s net profit (excluding China)
  • As the recently-launched China Business is at the initial investment phase, an operating loss of S$1.56 million was registered in 1H2016
  • In June 2016, iFAST China completed the sale of a 5% stake for US$1.75 million, leading to a gain of S$2.15 million for the Group. This gain was however recognised directly in equity, instead of income statement
  • The Directors have proposed a second interim dividend of 0.68 cents per ordinary share for 2Q2016 (2Q2015: 0.68 cents per ordinary share)
  • The Group is also updating its 2016 Dividend Guidance to:  “For FY2016, our Directors intend to recommend and distribute dividends of 60% or more of our Group’s net profit (excluding our China operation, and exceptional items)”

To view the full announcement, please click on the button below.

Real Estate Investar Passes 200,000 Member Milestone and Facilitates Over $17m of Property Sales in June

29th July 2016, ASX Announcement

Highlights of June 2016 Quarter:

  • Passed 200,00 membership milestone with 48.0% year on year growth;
  • Commenced roll out of direct real estate sales delivering $17 million in transactions in June and generating $0.8 million in commissions for Real Estate Investar;
  • Completed acquisition of The Property Factory to provide in house real estate agency sales experience; and
  • Signed partnership agreements with Domain and APM PriceFinder.

Real Estate Investar Group Limited (ASX: REV), a leading provider of online services to Australian and New Zealand property investors, has released its 4C statement for 3 months to the end of June 2016.

The June quarter was a period of strong growth for Real Estate Investar highlighted by passing 200,00 members, and successfully refocusing the business onto real estate transaction services.

To view the full announcement, please click on the button below.

YPB Signs Supply Agreement with Leading Brands Packaging Company

29th July 2016, ASX Announcement

  • Supply Agreement signed with Impact International to supply anti-counterfeit solutions and consumer engagement technology .
  • YPB Groups signs supply agreement with Impact International to supply anti-counterfeit tracer technology and consumer engagement solutions to Impact’s clients
  • Impact International is fast growing, producing approximately ten million unit per annum
  • Impact produces packaging tubes for brands including Colgate, Deep Heat and Nestle
  • Further validation of YPB’s end-to-end technology

Anti-counterfeiting and consumer engagement technology company YPB Group Limited (ASX:YPB) has signed a memorandum of understanding (MOU) and supply agreement with Sydney-based packaging company Impact International.

Under the agreement, YPB’s patented anti-counterfeit tracer and consumer engagement technologies will be available to Impact International’s customer’s, which include many of Australia’s and New Zealand’s leading manufacturers of cosmetics, fast-moving consumer goods, pharmaceuticals, health products and nutraceuticals.

To view the full announcement, please click on the button below.

Folkestone’s Latest Blog: Seniors Living – Becoming a Mainstream Investment

Seniors Living – Becoming a Mainstream Investment
Adrian Harrington, Folkestone’s Head of Funds Management, latest article for the highly regarded Cuffelinks investment newsletter sets out the reasons why the seniors living sector is set to become a mainstream investment.
Read more.

Folkestone’s First Seniors Living Fund
The Folkestone Seniors Living Fund No.1 (FSLF) offers a unique opportunity to invest in a fund that will acquire a portfolio of high quality retirement living communities in Sydney.  This will be achieved by investing in existing retirement living communities and also by joint venturing with partners to develop and ultimately own such communities.

FSLF is expected to benefit from increasing demand for seniors living facilities and services driven by an ageing population and growing acceptance of retirement living communities as a quality housing option for Australia’s seniors population.

FSLF’s first asset is the award winning Watermark Castle Cove located on Sydney’s lower north shore.

FSLF is currently open for investment.
Read more.

Aeeris Quarterly Report June 2016: Solid Progress with Revenues and New Products, Robust Sales Pipeline

29th July 2016, ASX Announcement

Financial Highlights

  • Total cash receipts of $488,138
  • Cash receipts received from customers of $477,629 compared with the previous quarter of $483,390
  • Net decrease in cash held (cash burn) of $429,971 compared with $411,285 in the previous quarter
  • Cash position at the end of quarter (30th June 2016) of $1.73 million (unaudited)

Business Highlights 

  • Solid quarter of progress with implementation of new customers and new products.
  • Optimistic outlook for ongoing new sales activity, and expansion into new verticals and new markets.
  • Strong internal team cohesion, especially in sales and business development.
  • Ongoing optimisation of operations and review of expenses, cost reductions.

To view the full announcement, please click on the button below.

Analytica’s PeriCoach Sexual Health Indication Clarification from USFDA

29th July 2016, ASX Announcement

Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® system, is pleased to announce that it has received clarification from the US Food and Drug Administration regarding additional marketing claims for improved sexual function in women from strengthening their pelvic floors using the PeriCoach system.

Following recent discussions regarding the over-the-counter clearance for PeriCoach system in the US, the USFDA has confirmed that the PeriCoach may be marketed for sexual function under “general Wellness” claims. This allows the product to state, for example, that “Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.” This clarification provides a level of certainty when communicating the benefits of the PeriCoach with clinicians and members of the public.

To view the full announcement, please click on the button below.

Universal Biosensors FY16 Update: Net Profit Reported, Valuable Partnerships with Siemens and Johnson & Johnson

UBI has undergone an exciting period of change over the past 12 months. UBI reported strong first half results with Quarterly Service Fee revenues from the market leading OneTouch® Verio blood glucose strip product up 58%. In addition, operating expenses for the period decreased 20%, helping the Company achieve an improved bottom line. Importantly, UBI reported a net profit in Q2’2016.

UBI continues to enjoy valuable partnerships with two global healthcare companies, Siemens and Johnson & Johnson. During the year, UBI modified its collaboration agreement with Siemens to focus their collective product development resources on enhanced products.

UBI has also implemented rigorous investment criteria to ensure its product development pipeline is on the right track. As a result, the Company’s development pipeline has been consolidated during 2016 in order to maximise return on investment for UBI shareholders.

ABOUT UNIVERSAL BIOSENSORS

Universal Biosensors (ASX:UBI) is a specialist medical diagnostics company developing and manufacturing test systems for point-of-care (POC) medical professionals and home use.

UBI’s core technology is a disposable, multi-layer test strip, which uses its proprietary electrochemical sensor to rapidly and accurately measure biomarkers in the blood.

The first product developed by UBI with LifeScan (a Johnson & Johnson company) is a blood glucose measurement device and is on the market and generating revenues for UBI. The second product developed by UBI in collaboration with Siemens Healthcare has also been launched.

The global point-of-care diagnostics market is estimated to be worth nearly US$17 billion a year and growing.

UBI is now extending its platform technology to new POC applications.

Analytica Quarterly Report: Cash Outflow Reduced by $824k, INOV8 Additional $500k Placement, FDA Clearance

Highlights:

  • Cash outflow reduced by $824k on previous quarter
  • INOV8 additional $500k placement
  • FDA Over-the-Counter clearance for PeriCoach
  • AutoStart Burette granted US patent

Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® System, is pleased to announce its Appendix 4C – Quarterly cash flow report for period ending 30 June 2016.

Analytica’s cost reduction measures have resulted in cash outflow of $881k for the quarter a reduction of $824k on the previous quarter. A share purchase plan and share placements in April increased capital by $2,105k. The company estimates a tax incentive R&D refund of approximately $1.3m next quarter. American Virgin Islands cornerstone investor INOV8 LLC has committed to further placements of $250k at the end of August and a further $250k at the end of September. This additional $500k in 2 tracts together with the cost reduction program extends Analytica’s cash well into the next calendar year. The loan facility of $400k from Chairman Dr Michael Monsour continues to be available.

Version 3 of the PeriCoach system has reached production and Analytica prepares to gather verification and validation data for this next gen device. Software development is on track as enhancements to the database are near completion and new features to the app, such as the Bladder Diary have been introduced. These user interface updates provide users with a comprehensive picture of treatment progress which motivates them to stay engaged. Compliance with the exercise programme is key to achieving positive results for pelvic floor exercise.

With FDA granting clearance, the PeriCoach System is a medical device with internationally accepted safety testing, supported by clinical papers and case studies and no longer requires a prescription. Analytica aims to ensure that the company’s commercialisation partner has a reduced time to market and support from the clinical community. This quarter, additional clinical papers and testimonials were collected along with case studies published in the peer reviewed Urologic Nursing Journal of the US Society of Urologic Nurses and Associates.

Analytica achieved a significant milestone this quarter after being granted patent protection for its AutoStart® burette. Obtaining this patent is another important step in the commercialisation of the AutoStart infusion system. The patent increases the market opportunity within the US and positions the company for additional license deals for the product.

Also in this period Analytica’s Australian partner, Medical Australia Ltd (ASX: MLA) also succeeded in having the AutoStart infusion system added to the Queensland Health tender list under their Tuta FirstFlow brand name. This permits any Queensland hospital or health clinic to buy the product.

“Reaching the US FDA over the counter clearance, launching new app features, garnering further clinical support and published evidence for PeriCoach in the first half of 2016 demonstrates our commitment to put Analytica in the best possible position for a partnership,” said Geoff Daly, CEO of Analytica. “The continued investment by our cornerstone investor INOV8 reflects confidence in our strategic direction.”

DeClout Complete Of The Incorporation Of Play-E TW

28th July 2016, DeClout  Ltd

The board of directors (the “Board” or “Directors”) of DeClout Limited (the “Company”, and together with its subsidiaries, the “Group”) refers to the Company’s announcements on the proposed increase in shareholding in a subsidiary and acquisition of indirect subsidiaries on 22 July 2016 (“First Announcement”) and 25 July 2016 (collectively, the “Announcements”). Unless otherwise defined herein, all capitalised terms shall have the same meanings ascribed to them in the Announcements.

Completion of the Incorporation of an Indirect Subsidiary, Play-E TW

The Board is pleased to announce that the Target has completed the incorporation of Play-E TW in Singapore as at the date of this announcement, with an issued and paid-up share capital of S$180,000 comprising 100 ordinary shares.

The Target subcribed for 75 ordinary shares of Play-E TW for S$135,000, whereas other independent third parties have subscribed for the balance of 25 ordinary shares of Play-E TW for S$45,000.

Accordingly, as at the date of this announcement, the Target holds 75.0% interests in Play-E TW, and Play-E TW now forms part of the Target Group as an indirect subsidiary of the Company.

To view the full article, please click on the button below.

Leaf Resources July 2016 Update: JV with Claeris, Edison Research Report Released, Investor Presentation

Leaf Resources features as a Spec Buy in The Australian
The renewables play has won US backing that is bigger than Texas: a JV with Dallas-based renewables giant Claeris to develop Leaf’s homegrown process that converts biomass into cellulosic sugars…read more>>

Edison Research Report Released
Claeris JV to accelerate GlycellTM commercialistion
Leaf Resources has entered into agreements with US-based Claeris,LLC to establish a JV entity, Leaf Development, to develop up to five renewable chemical projects. Read the full report here>>

Investor Presentation
New investor presentation released….click here>>

Leaf in the News
Following the release of Leaf Resources silica announcement, we have received some media coverage 

June 2016

Oceans to hold more plastic than fish by 2050?

Ellen MacArther report says there will be more plastic than fish in the sea
As reported by The Guardian earlier this year, the Ellen MacArthur report highlights that new plastics will consume 20% of all oil production within 35 years, up from an estimated 5% today…read more>>

iSentric June 2016 Quarter: Cash Receipts Increased 120%, Product Offerings Expanding, 2.43 Million New Paying Users

28th July 2016, ASX Announcement

Highlights:

  • Cash receipts for the June 2016 quarter increased 120% over the previous corresponding period to $3.35 million
  • Management is continuing to expand product offerings in Indonesia, Thailand and Myanmar
  • Successfully acquired 2.43 million new paying users during the quarter in the Digital and Media Services segment, which is ahead of the 1.5 million per quarter forecast

Cash receipts of $3.35 million for the June quarter represented the strongest quarter for the year. During the quarter the Group received a large contribution from a Malaysian telecommunications business, resulting in an 8-0% increase in recipets compared to the March 2016 quarter and 120% increase compared to the June 2015 quarter.

The operation in Thailand made a small contribution to cash receipts, while the Myanmar operation will not begin contributing to cash until the second quarter of FY2017.

To view the full announcement, please click on the button below.

To view the full results, please click on the button below.

Booodl FY16 Update: 17,338 Shopper Visits Influenced, 20,000 Stores, SDO Launched

Following a $2.8 million funding round led by Scentre Group in late 2015, Booodl has made significant progress in its mission of making it easy to find the right store selling what you want. We have influenced 17,338 shopper visits since February, have well over 20,000 stores on Booodl and validated that physical retailers will pay for a service that helps them get discovered and drive sales.

Booodl also launched StoreDiscoveryOptimisation.com (SDO) as a resource for stores, brands and shopping malls to improve their discoverability (we spoke about this topic on Sky News Australia).

Also in the past 12 months, the Booodl website was launched, both the Android and iOS apps were revamped, and Booodl for Apple Watch was released. The app was consistently featured as a top shopping app, and we were nominated for Retail Small Business of the year and Inside Retail Customer Excellence Award.

ABOUT BOOODL 

Booodl is an app that simplifies local shopping by; making it simple to list products you want to buy, locating local stores through geo-notification push reminders and location-based search, instant messaging with stores, and in-app purchasing.

The User problem/solution is validated and retail stores have embraced the value proposition. Capital is being raised to continue R&D, grow in Australia and launch internationally.

Actinogen Medical Announces Landmark Research on Excess Cortisol and Alzheimer’s Disease

28th July 2016, ASX Announcement

  • Australian CSIRO and university funded AIBL study links excess cortisol and Alzheimer’s disease.
  • Anti-Alzheimer’s compound Xanamem™ in clinical testing blocks high cortisol (“stress” hormone) associated with disease progression.
  • Landmark research on disease mechanism and Actinogen Medical’s Xanamem™ presented at Alzheimer’s Association International Conference (AAIC) in Toronto 22nd-28th July.

Actinogen Medical (ASX:ACW) announced today results of its lead compound, Xanamem™, a novel, orally administered 11β-HSD1 inhibitor, which demonstrated in a Phase I study that it significantly inhibited production of cortisol in healthy volunteers and successfully crossed the blood-brain barrier. A separate study, the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), sponsored by the CSIRO and a number of Australian universities, showed a correlation between elevated cortisol in the blood of a healthy aged population and the subsequent development of Alzheimer’s disease in these individuals. When individuals also evidenced a broad build-up of beta-amyloid plaques in the brain, their chances of developing Alzheimer’s disease increased even further. The AIBL study (n=416) concluded that targeting ways to lower excess cortisol should be undertaken in battling Alzheimer’s disease in the elderly. Both studies were presented at the AAIC, the world’s largest Alzheimer’s Dementia meeting, taking place this week in Toronto, Canada.

To view the full announcement, please click on the button below.

To download the more information on Cortisol Hypothesis AAIC Supplement, please click on the link below. 

Proteomics International Quarterly Report June 2016: Cash Flow Strengthened & Cash Burn Reduced

28th June 2016, ASX Announcement

Life sciences comp-any Proteomics International Laboratories Ltd (ASX: PIQ) )the Company, PILL), is pleased to provide the following update on its business activities for the three month period to 30 June 2016.

Building on previous announcements PILL has strengthened its cash flow and reduced quarterly burn. Significant progress has been made towards the commercialisation of the Company’s lead diagnostic product, PromarketD, whilst analytical operations continue to expand.

Financial Highlights

Operating cash inflow for the June quarter more than doubled as compared to the previous quarter, whilst expenditure remained at similar levels and in line with budget. The net results was a reduction in cash burn to $204,000. The growth in revenue has led to Analytical Services annual income increasing 33% year on year to $0.81 million.

To view the full announcement, please click on the button below.

iComplii Now Available on Apple App Store

iCompLii has this week uploaded the iCompLii App to the Apple App store.

This is a great step forward for iCompLii, because it means that it is now easier than ever for individuals to signup and create an iCompLii profile and upload certificates, removing the tech barrier for entry for the blue collar workers.
The iPhone and iPad versions is available via the App Store and the Android version is just weeks away, this is a positive game changer for iCompLii and continuing the awesome traction we are already experiencing.
Those that are interested in a copy of the app, it is available by searching “iCompLii” on the app store.

Alcidion Appoint Resapp Health Co-Founder Brian Leedman

28th July 2016, ASX Announcement

Alcidion Group Limited (ASX: ALC), a global leader in Clinical Informatics, today announced the appointment of Mr. Brian Leedman to the bord of the Company. This move comes at a pivotal time for Alcidion as the Company looks to expand market share of their award-winning Miya Platform product internationally.

Mr. Leedman is  the co-founder of Resapp Health (ASX: RAP) where he currently serves in the role of the Executive Director and Vice President, Corporate Affairs. Mr Leedman is a marketing and investor relations professional with over 10 years’ experience in the biotechnology / healthcare industry. Prior to Resapp Helath, Mr. Leedman co-founded Enigma Therapeutics which listed on the ASX in 2013 as OncoSil Medical Limited.

Mr. Leedman previously served for 10 years as Vice President, Investor Relations for pSivida Corp. which is listed on the ASX and NASDAQ.

To view the full announcement, please click on the button below.

BioDiem FY16 Update: Nasovac-S Export Approved, Clinical Trials Due to Finish FY17, New Formulations Planned

BioDiem’s focus is the prevention and treatment of infectious diseases. Royalties flow to BioDiem from sales of Nasovac-S™ in India, a flu vaccine manufactured by Serum Institute of India (SII) under licence from BioDiem.

In FY16, after achieving approval to export Nasovac-S, SII entered into international distribution agreements with multinational Cipla. BioDiem’s Chinese flu vaccine licencee, the Changchun BCHT Biotechnology Company commenced clinical trials due to finish in FY17. These are necessary prior to approval and launch of the flu vaccine in the enormous China market. BioDiem’s subsidiary, Opal Biosciences conducted formulation and mechanism of action studies supporting BDM-I’s activity against treatment-resistant bacteria, including Golden Staph. New formulations of BDM-I are planned for FY17.

ABOUT BIODIEM

With rising global concern about pandemic infections, “superbugs” and antibiotic resistance, BioDiem is well-positioned with its focus on commercialisation of infectious disease therapies. We have an established ‘flu vaccine licencing business already with commercial partners in India and China. Our revenue comes from licence fees and royalties on sales. The seasonal influenza vaccine Nasovac-S™ is marketed in India and has recently received WHO prequalification which allows export to new markets.

BDM-I, our patented antimicrobial compound, targets treatment of serious human infections and is in preclinical development through our subsidiary, Opal Biosciences Ltd.

BioDiem Entitlement Offer Closes Friday July 29th

BioDiem’s pro rata nonrenounceable Entitlement Offer to raise up to $1,250,000 (before costs) is closing soon.

Funds will be used to progress the next phase of commercialization of BioDiem’s influenza vaccine (LAIV) licensing business; and its antimicrobial, BDM-I, in development for the treatment of infectious diseases through BioDiem’s subsidiary, Opal Biosciences Limited (“Opal Biosciences”).

A copy of the BioDiem Prospectus and a personalised entitlement and acceptance form, including BPay details has been mailed to shareholders. The Prospectus is available on the website.

Should you wish to receive additional information, please click the button below. 

MyWave Receives Frost & Sullivan’s Global Enabling Technology Leadership Award

July 26th 2016, PRNewswire

Based on its recent analysis of the customer experience market, Frost & Sullivan has selected intelligent assistant company MyWave as the recipient of its 2016 Global Enabling Technology Leadership Award.

According to Alexander Michael, Director of Consulting for Frost & Sullivan, “The Award reflects MyWave’s overall technology leadership in the global intelligent assistant market.”

The world is about to cross the inflection point in the progress of artificial intelligence (AI). Intelligent assistants are probably the best example of a practical AI-based system, but many so-called intelligent assistants underwhelm customers because the intelligence displayed is severely limited and their use cases are restricted to customer self-service within tight boundaries.

“In this context—and unlike its peers that have simply offered incremental upgrades of their legacy technologies—MyWave’s Frank is a wholly innovative solution,” said Michael.

To view the full article, please click on the button below.

Peppermint Roadshow Presentation July 2016

27th July 2916, ASX Announcement

Vision Statement

Our aim is to provide mobile payments, money services and remittances to anyone, anywhere in the world, especially those not currently linked to traditional banks.

Company Snapshot

ASX listed Fintech company targeting the global mobile payments sector
Listed on the ASX in December 2015
Founded March 2015
What we do;

  • Operate an established and commercially developed mobile phone banking, payments and remittance platform in the Philippines
  • Deliver mobile payment services to facilitate financial inclusuion and consumer convience
  • Imporve business effiencnt and dervie revenue forf commercial clients and agent networks

To view the full announcement, please click on the button below.

Analytica Share Placement of $500k to Cornerstone Investor

27th July 2016, ASX Announcement

Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach®  System, is pleased to announce the further placement of new fully paid ordinary share to our American Virgin Island cornerstone investor INOV8 LLC.

Shares will be issued in 2 tranches at an issue price of $0.007 per share. The first tranche is for 35,714,285 shares with a settlement date of 31st August 2016. The second tranche is for 35,714,286 shares and a settlement on the 30th September 2016/ These allotments total $500,00.

These funds, together with anticipated R & D tax incentive for 2016 and the expenditure reduction program, strengthens Analytica’s cash postilion.

To view the full announcement, please click on the button below.

Altech Raises $10 Million in Oversubscribed Share Placement

27th July 2016, ASX Announcement

Highlights:

  • $10 million raised via share placement to institutions, professional and sophisticated investors
  • Placement was heavily oversubscribed
  • A range of quality institutional investors join Altech’s share register

Altech Chemicals Limited (Altech/the Company) (ASX: ATC) has welcomed a number of institutional investors onto its share register as a result of a $10 million oversubscribed share placement (the Placement). Placement shares will be issued at 14 cents per share, which represents a 14% discount to the price of the Company’s shares at the close of trade on the Australian Securities Exchange (ASX) on 21 July 2016.

Funds raised from the Placement will be applied to finalising the detailed design of the Company’s proposed Malaysian high purity alumina (HPA) plant, completion of independent due diligence associated with finalising debt financing, closure of debt financing and general working capital purposes.

To view the full announcement, please click on the button below.

OncoSil Medical Quarterly Activities & Cash Flow Report June 2016

27th July 2016, ASX Announcement

OncoSil Medical Ltd (ASX: OSL) (Oncosil of the Company), a late stage medical devices company focused on localised treatments for patients with pancreatic and liver cancer today released its Appendix 4C – Quarterly Cashflow report for the quarter ended 30 June 2016 (the Quarter). All financial results are in Australian dollars and are unaudited.

Highlights for the Quarter

  • Filed IDE Amendment with u.S. FDA
  • Further submission to the Notified Body for CE mark applicatiopn responding to all questions
  • Michael Warrener, appointed Global Head of Sale and Marketing
  • All 30 June 2016 options exercised for cash, with recipts of $0.9m
  • Cash outflow form Operations of $2.0m for the Quarter – closing cash balance of $13.4m

To view the full announcement, please click on the button below.

Long Pipes FY16 Update: Capital Raise for $1.5M Oversubscribed, Major New Project, New Board Member

  • First test pipes for FMG Christmas Creek.
  • New Pipe Production Machine operational.
  • Capital raising for $1.5M oversubscribed.
  • Major new projects for:
    - Geothermal in development with new high pressure, high temperature, corrosion resistant, long life pipes in discussion and development
    - 200kms in discussions for Australia as part of 400kms overall to start in last quarter 2016,
    - 700kms in discussion for unnamed party under agreement over the next 2 years
    - Multiple Pipe tests have demonstrated excellent performance with 136 bar or 1,900 psi without failure.
  • Mr David Gow has been appointed to the Board of Long Pipes, he has a background in finance.

ABOUT LONG PIPES

Disruptive Technology in a Disrupted Market: Pipelines have been made with small sections of pipe joined together for hundreds of years, it is difficult expensive and prone to leak. Long Pipes produces and sells the Fluid Highway™ an all composite continuous pipe produced in the field without joints “no welders”. This disruptive solution is being recognised globally by the major oil and gas, irrigation companies and governments for a range of projects. The initial project is for FMG; with other projects of up to 700kms of pipe in the coming years; next is a major Australian gas company initially for 500kms. Overall in Australia we have discussions on a nominal 2,000kms of pipe over the next 2-3 years. Internationally we have discussions and interest on tens of thousands of kilometres for a range of applications.

Peppermint Innovations June 2016 Quarterly Report

26th July 2016, ASX Announcement

Peppermint Innovation Ltd (ASX: PIL) (the Company) today releases its Appendix 4C – Quarterly Cash flow report for the period ended 30 June 2016. (Please note that the real progress reported below by the Company was made at or after the end of this quarter with little impact on cash flows during this quarter).

Highlights and key updates

1. Program going forward: On 27 June 2016 the Company announced its plans going forward in a letter to Shareholders. The Company emphasised:

  • The aim of the Company is to provide mobile payments, money services and remittances to anyone, anywhere in the world, especially those not currently linked to traditional banks.
  • The Company is currently operating in the Philippines, and has partnered with some of the largest financial institutions in the industry.

To view the full announcement, please click on the button below.

Panalitix FY16 Update: $4.5M New Capital Raised, Client Count Increased by 70%, Headed to IPO in 2017

In the past 12 months PANALITIX has increased its monthly recurring revenue by 70% to $250K per month. It increased its client count by 70% to 750 Accounting firms. It has released 2 new products and it expanded into the UK and the USA. PANALITIX made 2 acquisitions to KickStart its USA business. It has raised $4.5M in new capital. We are raising capital now as we head to an IPO in 2017.

ABOUT PANALITIX 

At PANALITIX we help Accountants in public practice transform businesses. Over the last 20 years, co-founders, Colin Dunn and Rob Nixon, have helped tens of thousands of accountants improve their firm’s operating performance.

Built on a foundation of coaching, content and technology, PANALITIX has created 4 SaaS platforms that help Accounting firms automate their marketing, automate their sales, train their people and automate the delivery of business advisory services. We are targeting 1.27M accounting firms on a global scale. Our average sale price of our subscription is $8,000 per annum per firm.

Trade Samurai FY16 Update: $1.4m Raised, Positive Reviews, Progress Ahead of Schedule & Below Budget

Trade Samurai has had a great year. It raised $1.4 million in our first round and beta launched the App in May 2016.  Reviews have been very positive.

Progress has been ahead of schedule and below budget. Live forex trading functionality and revenue from Australian clients is expected to commence in Q4 2016.

International markets and broking licences are currently being negotiated and finalized. R&D grant application has been completed and submitted.

Second round capital raising is expected to open in Nov 2016 at a higher share price to the first round.

ABOUT TRADE SAMURAI 

Trade Samurai is an exciting new game based Forex trading App providing unsurpassed education, community sharing, ranking and mentoring.

Forex trading is the world’s largest market, with more than $5 trillion USD being traded daily.  Trade Samurai offers new and experienced global traders the most advanced, fun, educational and community focused environment to trade this exciting marketplace.

Players learn how to trade forex by playing games and simulations set in a Japanese Samurai themed environment.  Players must move through five different Dojos, complete various games and challenges, all the while learning about live Forex Trading.

There is simply nothing else like Trade Samurai anywhere!

RewardBet FY16 Update: New Version Ready to Launch with 5 Country Patents Granted

RewardBet’s now been granted five country patents, including Australia. They were invited to present at the world’s biggest startup conference in Paris in June – a nod to the innovation of the product.

They are about to launch their new version, which will be the world’s fastest betting interface. They have a world-wide distribution signed as well as NDA’s with other operators in many regions.

On the back of this, they are seeking expansionary capital at a significant discount for a limited time until the revenue from these overseas deals starts to flow.

ABOUT REWARDBET 

Described as one of the most innovative gaming developments in decades, RewardBet is a patent protected (50+ countries; granted and pending) and award winning software product designed to significantly enhance the betting experience for customers and increase revenue for operators across Racing, Sports and Casino.
With a major global licensing agreement signed and many very forward implementation discussions with operators including four Tier 1 totes, RewardBet is seeking funding for resources to implement current opportunities and invest in future B2B licensing deals.
It is a very low-cost operation with three years of traction and growth including three rounds of investment. The opportunity for high levels of free cash flow combined with IP protection provides upside to a healthy dividend return as well as an IPO exit or trade sale.

Crowd Mobile Investor Presentation July 2016

26th July 2016, ASX Announcement

 Growing m-payment Network

  • Global reach into 54 countries and connected to over 160 mobile carriers
  • The larger our m-payments network, the larger our addressable market
  • Further growth opportunities into Asia, Africa & LATM

Growing the Company 

We have implemented and are executing the following:

  • Launch new products into existing countries by leveraging our existing global m-payment platform
  • Grow m-payments network into Asia, Africa & LATM as the larger our m-payments network, the lager our addressable market
  • Exploring and extracting revenue synergies (product & customer databases) between the Q&A and Subscription division

To view the full announcement, please click on the button below.

Executive Director of Alcidion to Present at BioShares Biotech Summit

26th July 2016, ASX Announcement 

Alcidion Group Limited (ASX: ALC) is pleased to announce that Executive Director, Mr Nathan Buzza, will present a paper on “Opportunities for Investment in Digital Health” at the Bioshares Biotech Summit on July 29th 2016 in Queenstown, New Zealand.

A copy of the presentation, inclusive of presentation notes is included withthe announcement.

ABOUT ALCIDION GROUP

Alcidion is the brainchild of the former CEO of the SA Heath Department and Professor Malcolm Pradhan, a Stanford qualified physician. Over the past decade, Alcidion has invested $15m into the R&D of the cutting edge Clinical Decision Support System and is now focussed on commercializing the technology.

The introduction of Patient Protection & Affordable Care Act 2010 (“Obamacare”) requires US hospitals to accelerate the adoption of Electronic Medical Records.  Alcidion is a leading supplier of these systems in Australia and is now seeking to expand its operations into the United States.

To view the full announcement, please click on the button below.

Alcidion’s Professor Malcolm Pradhan Presents at Health Informatics

26th July 2016, ASX Announcement

Overview

  • Why are smart machines are important for health care
  • The emergence of deep learning
  • Deep learning vs existing methods
  • Some early results
  • Practical tips on getting started
  • Future directions

Health informatics company with products in  

  • Patient flow & bed management
  • Emergency Department
  • Outpatient and referals management
  • SmartForms, clinical decision and support (CDS)

A health informatics approach 

  • Computer should play a more active role in health care
  • Assist clinical staff so that the right thing is easier than the thing to do

We want to turbo charge our products using advances in smart machines 

To view the full presentation, please click on the button below.

Why Commercial Agencies Turn to Surga Central

There’s a reason leading agencies use Surga Central to market commercial property

First Class Brand representation
Generate professional brochures in seconds to create a positive brand image and deliver a consistent message to your contacts.

Enquiry Actions
Track leasing and investor prospects by action performed. Report to owners and quickly identify the key prospects seeking to lease or buy your commercial property.

Smart Appointments
Create appointments for tenants, owners and enquirers. Have Surga Central suggest the participants and location. Sync to your Exchange account or Exchange Online account.

Visualise Occupancy
View interactive stack plans, lease expiry profiles and tenant mix charts. Improve your ability to pitch and secure quality stock.

Email Campaigns
Create and deliver targeted email campaigns and track which contacts open your campaigns.

YPB Group Strengthens Team with CFO Appointment

25th July 2016, ASX Announcement

YPB Group Limited (ASX: YPB) is pleased to announce the appointment of Jason York as Chief Finance Officer (CFO) of the company, effective immediately.

Jason joins us from ConvaTec (a US$1.7b revenue multinational medical technology company) where he was the Vice President of Finance for the Asia Pacific region. Jason is a senior finance executive who has a proven track record in developing high performing finance functions in multinational corporations across various geographies. Jason has strong commercial and financial experience having worked both locally and internationally in his 20-year career.

Jason holds a degree in Economics & Accounting from the University of Canterbury and is a member of the Institute of Chartered Accountants of Australia and New Zealand.

To view the full announcement, please click on the button below.

Thinxtra Makes Quick Progress Deploying Sigfox Network

22nd July 2016, IoT Hub By Peter Gutierrez

Local IoT network provider Thinxtra has announced that its rollout of the Sigfox network has now reached the milestone of 25 percent coverage of the Australia and New Zealand population.

Just three months after the partnership and network launch, Thinxtra said that the first phase of the rollout of Sigfox’s Low-Power Wide Area Network (LPWAN) in Sydney, Melbourne and Auckland is now complete, encompassing 9.6 million people in total.

Within Australia alone, Thinxtra said that 24.2 percent of the population is covered by at least one base station, with 21.4 percent being covered by two or more.

To view the full article, please click on the button below.

Panalitix Joins ASX Tech Rush with $20m IPO

25th July 2016, AFR by Yolanda Redrup

The throng of tech companies listing on the ASX is continuing into the second half of the year, with digital accountant community platform Panalitix looking to raise up to $20 million by hitting the boards.

Panalitix follows on from cyber safety business Family Zone, which filed a prospectus to list on the ASX this month.

The company, which provides accounting firms with access to an online library of resources and training courses for their staff, as well as client monitoring and marketing automation tools, is raising $2-3 million pre-IPO and $10-20 million when it lists in early 2017.

Co-founder and chief executive Rob Nixon said going public would help the business expand more quickly in the United States.

To view the full article, please click on the button below.

Sun Strategies Announcement: PEGRight ‘Product’ Launches, First Sale to Leading Industry Specialist

Sun Strategies Australia Announcement Regarding PEGRight Cyber Space Specialists

Ed Manners, Chairman and CEO of the Sun Strategies Group, an investor in PEGRight Inc and their non Executive Director advises that PEGRight is making great progress in launching its business which finds cyber intruders quickly.

PEGRIGHT is today’s Sherlock Holmes, finds cyber intruders. Flawless launch continues…..
Todays news is PEGRight Consulting 2016 profit accelerates and PEGRight Product Division achieves first sales of $175,000 in July 2016. PEGRight is a global opportunity. High capital gains potential. Founders Paul Bailor CEO and Eric Uythoven CTO are specialists with years of experience at Lockheed Martin. Global Patent pending. No prior art identified by PEGRight’s lawyers.

  • PEGRight consulting. 2015 achieved breakeven. 2016 contracted sales $2.0 million = profits $500,000. Sales + profit growth to continue.
  • PEGRight Product (1) launched to the industry at the US Cloud Identity Summit in 6/2016. First sales $175,000 made. Initial sales team and distributors being activated. Good revenues expected to emerge in Q4 2016. PEGRight Consulting clients likely to be early adopters.
  • PEGRight Product (2) is a next generation cyber security business that has developed new alternative methods for rapidly detecting data breaches though software algorithms that analyze users’ patterns of activity and behavior. PEGRight’s key breakthrough reduces the current average detection time of 65 days to a few days, hours, and even minutes.
  • PEGRight Product (3) is developing a family of Identity and Access Management (IAM) products that help our customers and Strategic Partners quickly resolve “identity security pain points” in a highly cost effective manner. Included in the PEGRight family of IAM products is our new Identity Intelligence and User Behavior Analytics capability presented at the June 2016 Cloud Identity Summit. These first sales are a direct result of the product strategy set in motion by Eric Uythoven, the PEGRight CTO. PEGRight has completed extensive product development on multiple products within our IAM family of products with the first fully operationalized products now being created.

BPS Technology Ltd (ASX: BPS) FY16 Update: Bucqi Launched, New Chinese Distribution Channel & Shareholder Return of 24%

In FY16, BPS developed its business to a new level with the rollout of its Bucqi loyalty, rewards and mobile payments platform. Bucqi aims to be the best value rewards program on the market with a compelling offer to attract consumers to merchants (of which BPS has more than 24,000 clients on its Bartercard trade exchange).

A newly opened Chinese distribution channel via Alibaba and partnerships with insurer Honan and marketer Gruden should enhance near-term value. Investors are cottoning onto BPS’ potential with FY16 total shareholder return of 24% including two healthy dividends

ABOUT BPS TECHNOLOGY 

BPS Technology Limited (ASX: BPS) provides technology and payment platforms centred on SME’s. It is a profitable business operates in eight countries, capitalising on a number of significant growth opportunities.

BPS operates three highly complementary and scalable businesses – Bartercard, bucqi and TESS.

Bartercard operates the world’s largest trade exchange. It allows SME’s to conduct $600m of additional business without the use of cash.

bucqi is a disruptive payment, loyalty & rewards platform that allows consumers to pay merchants via an app for goods and services without using a card or cash. Consumers earn and redeem reward points across a wide range of merchants.

TESS (Trade Exchange Software Services) develops software for trade exchanges. It is recognised and recommended as the preferred software by the global governing body of the industry.

Altech Chemicals Capital Raising Update July 2016

22nd July 2016, ASX Announcement

Altech Chemicals Limited (Altech/the Company) (ASX: ATC) advises that further to the suspension in trading of the Company’s securities on the Australian Securities Exchange (ASX) pre-open this morning, Perth stockbroking firm DJ Carmichael Pty Ltd (Lead Manager) and Hong Kong stockbroking firm Empire Capital Partners (Co-Manager) are arranging a placement of fully paid ordinary shares of the Company to a variety of professional and sophisticated investors (the Placement).

Funds raised by the Placement will be applied to the detailed design of the Company’s proposed high purity alumina (HPA) plant at Johor, Malaysia, the completion of debt financing for the project and for general working capital purposes.

To view the full announcement, please click on the button below.

MyWave FY16 Update: Best Enabling Technology Award, UK Expansion, In Third Successful Capital Round

MyWave is in its third successful capital round and invites further interest. We have received a Best Enabling Technology Award for Customer Experience from Independent Analyst Firm Frost & Sullivan,  are live in market with our Intelligent Automated Energy Switching service and now expanding that into the UK with very attractive revenue metrics.  Peter Diamandis author of Bold, Abundance and Singularity University has agreed to become an Advisor to MyWave and we are delighted to be working with Peter advancing exponential growth and the positive disruption of key industries globally.  We are enhancing customer experience and enabling the Fourth Industrial Revolution with MyWave’s unique and world leading Intelligent Assistant that combines machine learning, personal data and commerce.

ABOUT MYWAVE 

MyWave is a thought leading technology company re-imagining the future of digital relationships between businesses and consumers.

Founded by Geraldine McBride, former President of SAP North America, MyWave flips the traditional Customer Relationship Management (CRM) model on its head by putting the customer in control of their data via a Virtual Personal Assistant (VPA) called Frank®. Frank personalises the consumer/brand relationship, making life easier by connecting people in a frictionless, relevant and customer outcome-focused manner.

MyWave is enjoying strong market momentum within the banking, tourism, retail, utilities and automotive sectors, described as ‘revolutionary’ and ‘an enabler of new digital customer centric business models’.

Martin Aircraft Company Teams Up with Oakley and Bubba Watson to Design Golf Cart Jetpack

Ferrying your golf bags and equipment around the golf course has taken on a whole new dimension as the world’s first flying golf cart takes to the skies. The Golf Cart Jetpack is the result of a collaboration between Axstra past client Martin Aircraft Company, maker of the Martin Jetpack, sporting equipment manufacturer, Oakley, and pro golfer Bubba Watson.

Bubba Watson, two time Masters champion and currently fifth ranked golfer in the world, is known for pushing the boundaries of his sport in an attempt to make it faster and more fun. Three years ago he teamed up with Oakley to create the world’s first hovercraft golf cart. With golf returning to the Olympics this year after an absence of more than a century, Bubba and Oakley wanted to take this idea to the next level and approached Martin Aircraft Company to develop the concept based on its current pre-production prototypes. The outcome of this venture can be seen in the Bubba’s Jetpack video below.

Universal Biosensors H1 2016 Results, Presentation and Audio Presentation

21st July 2016, ASX Announcement

Highlights:

  • Total revenue of $10.5 million in 1H16, up 41% on1H15
  • Revenue from Quarterly Service Fees – generated by sales of glucose test strips – $10.3 million, up 58% on 1H15
  • Net loss of $1.2 million, improvement from 1H15 net loss of $4.1 million and trending towards breakeven
  • R&D expenditure $7.9, down 20% on 1H15 due to refocus of product development pipeline and containing costs
  • Cash balance of $13.2 million, up from $10.7 million

Universal Biosensors (ASX:UBI) today released its financial results for the first half of 2016.

To view the full announcement, please click on the button below.

To view the Presentation, please click on the button below.

To view the Audio Presentation, please click on the button below.

Flying Golf Cart Keeps Jetpack Dream Alive

20th July 2016, NZ Herald By Christopher Adams

The Martin Jetpack’s potential to become an airborne golf cart is helping keep founder Glenn Martin’s dreams for flying machine alive, says the aircraft maker’s chief executive.

The Christchurch-based Martin Aircraft Company has teamed up with sunglasses manufacturer Oakley and world number five golfer Bubba Watson to market the golfing applications of the New Zealand-developed jetpack.

A two minute YouTube video shows Watson talking-up the machine amid scenic clips of it flying above a South Island golf course.

The jetpack maker has been more focused in recent years on the professional “first responder” applications such as search and rescue and fire fighting.

That was one of the reasons for Glenn Martin’s sudden resignation from the firm’s board last year, just three months after its listing on the Australian stock exchange.

To view the full article, please click on the button below.

Leaf Resources Signs Joint Venture to Develop Five Projects

20th July 2016, ASX Announcement

Highlights

  • Leaf Resources Ltd enters into binding agreemnts with Claeris, LLC of Dallas, Texas USAto establish a joint venture entity, Leaf Development, LLC
  • Leaf Development, LLC was formed to develop up to five renewable chemical projects utilising Leaf Resources’ proprietary Glycell™ process
  • Claeris has a proven track record of developing large-scale, financially successful renewable projects
  • Claeris will invest USD$500,00 in Leaf Resources
  • The Directors of Leaf Resources believe that the agreement with Claeris will:
    - Lower transaction execution risk given Claeris’ strong track record of sourcing funding, and building large-scale commercial renewable projects;
    - Accelerate the speed of project development;
    - Facilitate more favourable commercial terms for projects;
    - Increase the field of opportunity for the deployment of Leaf Resources’ technology.

Leaf Resources Ltd (ASX: LER, “Leaf” or “Leaf Resources”) is pleased to announce the signing of binding legal agreements with US-based project developer  Claeris, LLC (“Claeris”), to establish a joint venture (JV) entity, Leaf Development, LLC (“Leaf Development”), for the purpose of developing up to five renewable chemical projects that utilise Leaf Resources’ proprietary Glycell™ process.

To view the full announcement, please click on the button below.

Crowd Mobile June Quarter Trading Update; Record Revenue Month, Tenth Consecutive Quarter of Growth

19th June 2016, ASX Announcement

Highlights for the June Quarter 

  • Tenth consecutive quarter of growth in total billed messages from the Question & Answer (“Q&A”) division with a 12% increase over the previous quarter to 2.6 million messages.
  • Q&A division growing strongly in all key metrics with Jun-16 a record revenue month and further opportunities for growth in FY17.
  • Net Debt at 30 June 2016 of $14.8 million, a reduction of $3.7 million since December.
  • Unfavourable exchange rates impact on results with quarterly revenue increasing slightly over the previous quarter to $11.54m from $11.46m and underlying EBITDA down 90% to $2.93m.
  • Payment of second Track Vendor Earn Out of EUR2.5 million ($3.7million)
  • Continued strong generation of operating cash flows on a month-to-month basis in line with expectations
  • Commercial launch of the Company’s most successful Mobile App to date ranked #1 in its category across numerous countries.

Crowd Mobile Limited (ASX: CM8 & FWB-XETRA: CM3, Crowd Mobile, “the Company”) is pleased to report its unaudited quarterly results for the three months to 30 June, 2016, as its Q&A business continues to gain momentum and revenues continue to grow despite a number of headwinds.

To view the full announcement, please click on the button below.

Actinogen has US Patent Granted and Further Extends Xanamem Protection

20th July 2016, ASX Announcement

  • United States Patent granted for use of Xanamem™ in Alzheimer’s dementia and other diseases.
  • Xanamem™’s long patent life now further extended to 2031 in the US.
  • Comprehensive protection over Xanamem™ now received for most major markets.

Actinogen Medical Limited (Actinogen  Medical, ASX: ACW), is pleased to announce it has received official notification to grant from the United States Patent Office for the most comprehensive patent for Xanamem. This patent further extends the comprehensive cover for Xanamem through to 2031.

The patent ( US 9,365,654 B2) protects use of Xanamem™ for use in Alzheimer’s dementia and other relate diseases associated with the inhibition of the 11-beta-hydroxysteroid dehydrogenase (11β-HSD1) enzyme. Importantly this patent cover through to 2031 comes on top of previous approvals in most other major markets, including all European countries and the UK, Australia, Japan and China.

To view the full announcement, please click on the button below.

Bubba Watson Trials Golfing Jetpack in New Zealand

20th July 2016, Stuff NZ

American golfer Bubba Watson has taken to the skies, trialling a specialised jetpack in New Zealand.

The world No 5 teamed with sponsor Oakley for a novel way to get him around the course as he literally flew over the Methven Golf Club in the South Island.

“For the first time in 112 years, golf is part of the Olympics. That’s a big deal,” Watson, who is always up for a challenge, said in a promotional video for the flying golf cart.

To view the full article, please click on the button below.

Gray Line Coaches and NG1 TechFlo to be Allied Partners; US Department of Energy Grant Application Report

1. Sun Strategies Australia Announcement Regarding Gray Line Coaches and NG1 TechFlo

Ed Manners, Chairman and CEO of the Sun Strategies Group, an investor in NG1 Technologies Inc and their Deputy Chairman advises that Gray Line Worldwide, the world’s largest provider of sightseeing tours, had selected cleantech innovator NG1 Technologies as an Allied Partner to bring TechFlo Exhaust, NG1’s aftermarket exhaust system, to Gray Line licensees. 30,000 Trucks are involved. As an Allied Partner, NG1 joins a select group of brands whose products and services are available to Gray Line licensees, providing these companies with access to the advanced fuel savings of NG1 TechFlo Exhaust.  Gray Line Worldwide’s Allied Partners include several established and respected transportation industry companies, such as Bridgestone, Detroit Diesel, Motor Coach Industries and Prevost. Gray Line licensees are currently installing NG1 TechFlo Exhaust systems at select locations across the U.S., with plans to roll out the product to all U.S. locations in the coming months and eventually to international sites. A recent composite credential report concluded the average fuel saving from using the TechFlo system was 12.33%, double the competitors.

2. US Department of Energy Grant Application Report NG1 TechFlo and UPS

An important second matter is the US Department of Energy Grant Application Report. In February 2016 as part of the continued research NG1 solicited a Department of Energy (DOE) funding opportunity announcement (FOA) DE-FOA-0001384 Innovative Dual Fuel Aftermarket Emissions Solution with United Parcel Service (UPS).   The exploratory research program is to develop an advance emission control system for Class 7 and Class 8 heavy duty vehicles equipped with an alternative fuels product variant.  The research will lead to the elimination or mitigation of the negative effects of current Diesel Particulate Filters (DPF) and Selective Catalytic Reduction (SCR) after-treatment systems by replacing them with a combination of symbiotic technologies specifically designed to enhance fuel savings and promote complete combustion reducing emissions. This DOE Report is expected in the next two months.

US Residential Fund CEO Interview

US Residential Fund is an ASX-listed business that is seeking to raise capital in order to transform over time from a property owner to a fund manager that retains exposure to property assets. Starting with a portfolio of 140 established rental houses in three US states, the fund has paid a A$0.06c pa distribution, which equates to a 10% return against the current capital raising offer price.

The fund is moving into the attractive multifamily property asset class and has established infrastructure in the US and Australia, which can be readily employed to execute the funds management strategy.

Please listen to Andrew Meakin, Managing Director of US Residential Fund below.

Ai-Media FY16 Update: Broadcast Deal Signed with Seven Network, Mobile App Launched & US Subsidiary Established

Ai-Media signed a multi-year broadcast captioning deal with the Seven Network, covering all offline and live captioning for its television channels including Seven, 7Two, 7Mate and 7Flix. The contract commences on 1 August, ahead of the Rio Olympics which begin on 5 August. Additionally, contract extensions with both Foxtel and the Nine Network were secured. The Company has sustained its Captioning Quality record, with the most recent independent audits revealing scores of over 99.6%.

Development of the Visible Classroom product in conjunction with the University of Melbourne has continued, and a mobile app was launched in the App Store and Google Play store worldwide.  The App allows teachers to upload recordings from their classroom for analysis,  and download their transcript, analytics and insights that drive behavioural change.

In March 2016, Ai-Media Inc, a wholly-owned US subsidiary was established.

ABOUT AI-MEDIA

Ai-Media delivers live & offline television captioning under long term contracts for many Foxtel channels, education captioning for schools and universities, and high quality transcripts to 99.90% accuracy for government and corporate clients.

Ai-Media’s flagship technology solution, Ai-Live has proven effective in pilots supported by Commercialisation Australia for deaf students at school & university. Current clients include the NSW & Victorian education departments, & Macquarie University.

Bulletproof FY16 Update: Acquired Infoplex, Raised $3.8m, Over-Subscribed Share Purchase Plan

Bulletproof Group Limited (Bulletproof – ASX code BPF) enjoyed a very active FY16. The Company successfully acquired Infoplex in October 2015 for $3.55m, following a capital raising of $3.8m. A Share Purchase Plan in November was over-subscribed and raised a further $2m. The Company completed its acquisition of New Zealand AWS partner Cloud House in February 2016. 1H16 results included 90% revenue growth year on year, with strong underlying profitability growth compared with 1H15.

A new Melbourne office was opened in September 2015, and a new Sydney CBD office in June 2016, consolidating personnel from acquisitions and existing Rosebery offices.

Bulletproof was recognized as Frost and Sullivan's Managed Service provider of the year 2015, in November. Bulletproof presented with major client Crownbet at the AWS Summit in April 2016, demonstrating the key value Bulletproof delivers for customers.

Bulletproof also presented at the AWS summit Auckland in June 2016, co-presenting with customer Xero on cloud security best practices. These awards and events reflect Bulletproof's status as the leading end to end cloud services provider in Australia and NZ, and the only AWS Premier Consulting Partner across both countries.

Bulletproof's FY16 guidance indicates revenue growth of 67% year on year to $47m, with underlying EBITDA expected to be between $4.6m and $4.7m (up from $4.2m in FY15), and EBIT between $600k and $700k, slightly down on FY15's $850k, attributed to some customer-side delays in project work reducing profitability towards the end of the half. Customer wins throughout the year included Barbecues Galore, Nestle Australia, Minter Ellison and Fred Hollows Foundation.

ABOUT BULLETPROOF 

Bulletproof Group Ltd (ASX:BPF) is a publicly listed company with offices in Sydney, Melbourne and California. Founded in 2000, Bulletproof is the leading cloud services provider to business, enterprise and government customers.

Bulletproof has consistently been first to market with public and private cloud based services and innovations, including to launch a public cloud service in Australia and the first to launch a managed Amazon Web Services (AWS) offering. Bulletproof became an AWS Premier Consulting partner in 2013 and was re-certified in 2014. Bulletproof’s recent acquisition in the Cloud Consulting space has further enabled the company to help companies leverage the cloud as they disrupt their market, by simplifying the complexity of cloud and enabling its customers’ rapid transformation.

Peppermint Signs Agreement with Largest Bill payment Business in the Philippines

18th July 016, ASX Announcement

Highlights

  • Peppermint will be the first to provide a mobile application to CIS BAYAD CENTER, INC- the largest bill payment business in the Philippines.
  • Peppermint will work with the BAYAD CENTER (connected more than 200 billers) to provide its proprietary mobile application called the “Peppermint Payments Collection Solution”.

Peppermint Innovation Limited (ASX:PIL), an Australian mobile banking, payments and remittance technology platform focused on providing vital access to banking services for millions of people not currently linked to traditional banks, is pleased to announce that it has now signed a commercial agreement with CIS BAYAD CENTER, INC. (“CBCI”).

CBCI is a wholly owned subsidiary of MERLCO (Manilia Electric Co.), and the CIS Bayad Canter business model (the first of its kind in the Philippines) is now the leading brand in the country. Bayad Center provides the public with a worry-free payment collection in utilities, government service, telecommunications, cable TV, Internet, insurance & pre-need, healthcare, transportation, electronic wallet, credit card, real estate, financial services, art and entertainment and charity donations.

To view the full announcement, please click on the button below.

Video: iComplii Founder and CEO Jason Knight Featured on Ventured

iCompLii Founder and CEO Jason Knight talks about being the founder of iCompLii, some of the pains and also the gains. iCompLii is changing the way compliance is managed at both a personal and business level by removing the risks.


ABOUT ICOMPLII

iCompLii is revolutionising compliance for individuals and businesses with portable profiles for both human and physical assets, allowing flexibility and more certainty in workplaces that are becoming more contingent and a decreasing average length of employment.

The highly developed SaaS cloud-based platform handles the administration burden of complying with regulations and offers a service to candidates which enables them to efficiently store and manage all their personal and working information (including skills and certificates). iCompLii already has over 18,000 profile holders register since the platform was opened to the public in mid January 2016.

Last Chance for Legado Partners Melbourne Round Table Sessions

Private Capital Investments Round Table

Last Seats Available for next weeks Melbourne sessions.

Legado invites you to attend an early comment forum with current and prospective investors.

This session is to provide you with an opportunity to gain insight into specific deals in our pipeline and share with us your perspective on the opportunities in front of us.

There are some very good private businesses for sale in Australia where you can buy them at much lower price than listed shares or large corporates. There are also some very good management teams who run these businesses, who need cash and resources to help with the transition for the current owner.

If you would like to attend one of our sessions please follow the below links to get your free ticket through Eventbrite.com. Spaces are limited and registering is essential.

Is Legado right for you? 

If you have investable funds of $500,000 or more, you invest for the long term, you seek outstanding returns of 20%+, and you have an understanding or an appreciation of business then you may be a good fit. Please contact our office for further information or to understand the investment options that Legado offers.

Melbourne

Thursday 21 July 2016,
3:00PM & 5:00PM
Exchange Tower, 530 Little Collins Street, Melbourne.

Register Now

Sydney

Wednesday 17 August 2016,
3:00PM & 5:00PM
Level 9, 55 Hunter Street, Sydney.

Register Now

Canberra

Thursday 18 August 2016,
3:00PM & 5:00PM
Legado Office, Level 1,
113 Canberra Avenue, Griffith.

Register Now

Brisbane

Wednesday 21 September  2016,
3:00PM & 5:00PM
Brisbane CBD – venue to be confirmed.

Register Now

Martin Aircraft Company Signs Alliance Agreement with AvWatch

18th July 2016, ASX Announcement

Martin Aircraft Company is pleased to announce that it has signed a formal Alliance Agreement with AvWatch Incorporated, USA on 18 July 2016.

Avwatch is a US business that harnesses innovative and proven technologies to support, enhance and train Federal, state and local government agencies in support of homeland security and disaster recovery. The company was founded in 2008 and consists of nationally recognised Homeland Security experts who are well-versed in military, Federal, state and local disaster response planning and response protocols.

In terms of the agreement, Avwatch and Martin Aircraft Company will work together, along with input from already identified customers, to develop specific capabilities for the North American First Responder and Homeland Security sectors, key markets for the First Responder Martin Jetpack. The agreement also creates the platform to seek research and development funding for the further development of the Martin Jetpack to meet specific identified US first responder requirements.

To view the full announcement, please click on the button below.

WYZA Reaches Milestone of 200,000 Weekly Subscribers

WYZA.com.au, Australia’s fastest growing digital destination for people 50 plus today announced that it has just exceeded 200,000 subscribers to its weekly newsletter.

With the WYZA subscription base growing at a stunning rate – tripling in size over the last 12-15 months (59,000 in April ’15 to 151,000 in June ’16 and 200,000 in July ‘16), Managing Director Michael Farley said that reaching 200,000 subscribers was a significant milestone for WYZA – a 100% YOY growth – reflecting the massive engagement of our 50-plus demographic.

“200,000 weekly subscribers means that WYZA is better able to directly reach this exclusive and hard-to reach audience of people 50 , significantly out-performing our competitors in this category “ says Mr. Farley.

A recent research study* conducted by the site found that far from winding down, people over 50 are still forward and outward looking – wanting to travel, get or stay healthy, explore and buy new things or switch things up.

“60 is the new 40 with our users telling us they feel younger than their age and are optimistic about the future. Travel is the clear No 1 leisure passion for the WYZA audience with more than three quarters of them stating they intend to book a holiday within the next year. Getting or staying healthy, decorating or renovating their home and studying something new are all on the top of the list of things people over 50 are planning to do,” Mr. Farley added.

Less than 2 year old, WYZA.com.au has over 430,000 monthly visitors, generates more than 1.2 million page views, 24,272 Facebook followers and 200,000 weekly newsletter subscribers.

“The WYZA generation is a little older and a lot WYZA. They are savvy genre-defying consumers and are determined not to be ignored,” Mr. Farley said.

“What is also clear is that the old model of reaching people in this age group has changed. Some 88% told us that they dislike the way advertisers currently communicate with them. Remarkably, they spend an average of five hours a day on the internet, social media and their mobile phones.

“Against stereotype, 80% of WYZA respondents have a positive attitude towards technology, 90% have purchased online and 25% do so on a weekly basis.”

Video: LifeSherpa Investor Presentation June 2016

Please watch LifeSherpa’s Founder & CEO, Mr Vincent Scully, talk in further detail about the company and investment offer at the recent Sydney Investor Evening June 2016.


ABOUT LIFESHERPA

Lifesherpa is Australia’s first online financial advice service providing affordable, accessible financial advice for a new generation of Australians online combining technology with the human touch. Our proprietary online tools and efficient back office built on Salesforce, allows us to profitably service the needs of clients who do not have sufficient assets to be attractive to traditional financial planners.

For just $15/month, Lifesherpa members get their own advisor, access to the website resources and commission free advice on budgeting, debt elimination, super, insurance and home loans.

 

BioDiem Non-Renounceable Pro-rata Entitlement Offer Closes July 29th

15th July 2016

BioDiem’s pro rata nonrenounceable Entitlement Offer to raise up to $1,250,000 (before costs) is closing soon.

Funds will be used to progress the next phase of commercialization of BioDiem’s influenza vaccine (LAIV) licensing business; and its antimicrobial, BDM-I, in development for the treatment of infectious diseases through BioDiem’s subsidiary, Opal Biosciences Limited (“Opal Biosciences”).

A copy of the BioDiem Prospectus and a personalised entitlement and acceptance form, including BPay details has been mailed to shareholders. The Prospectus is available on our website.

ABOUT BIODIEM

With rising concern about viral infections, “superbugs” and antibiotic resistance, BioDiem is well-positioned with its focus on commercialisation of infectious disease therapies and vaccines. An established ‘flu vaccine licencing business is drawing revenue from commercial partners in India and China. Nasovac-S™ is marketed in India and has recently received WHO prequalification which allows export to new markets.

New anti-infectives are needed due to increasing resistance to existing antibiotics, more difficult-to-treat infections, and paucity new treatments. BioDiem’s subsidiary, Opal Biosciences Ltd is an innovative player in infectious disease treatment, targeting human infection – a high growth, commercially attractive market segment.

Video: 4Dx Investor Presentation June 2016

Please watch 4Dx’s Executive Chairman, Dr Andreas Fouras, talk in further detail about the company and investment offer at the recent Sydney Investor Evening June 2016.


ABOUT 4DX

4Dx brings a technological solution set to disrupt this multi-billion dollar sector through compelling unique competitive advantages over existing respiratory diagnostics. The respiratory diagnostic sector represents a global market of over $25B perannum. Currently served by out of date technology, 4Dx has enormous scope for financial success as well as life changing advancement for medicine.

Offering more detailed information, faster validation of treatment efficacy, lower costs, and reduced radiation dosage, 4Dx allows for earlier detection of disease and earlier intervention.The ability to identify lung issues earlier is creating a critical shift in the practice model from cure to prevention.

Video: Real Estate Investar Investor Presentation June 2016

Please watch Real Estate Investar’s Managing Director & CEO, Mr Clint Greaves, talk in further detail about the company and investment offer at the recent Sydney Investor Evening June 2016.


ABOUT REAL ESTATE INVESTAR

Real Estate Investar (ASX:REV) is a leading provider of integrated services to property investors to assist in the identification, analysis, acquisition, tracking and accounting of investment property. With over 190,000 investors accessing free online member services, and over 2,800 paying subscribers utilising its platform to build and manage their portfolios, Real Estate Investar helps investors generate wealth through property investment.

By providing an end‐to‐end online solution Real Estate Investar generates recurring subscription revenues as well as a number of transaction based revenues from services including mortgage broking and investment property sales.

 

Recording of Crowd Mobile Investor Webinar Available

15th July 2016, ASX Announcement

Crowd Mobile Limited (ASX: CM8 & FWB-XETRA: CM3) (Crowd Mobile or the Company) advises that a recording of the investor webinar which was held on Thursday 14 July  2016 is now available for viewing on the Company’s website via the following link:

To view the full announcement, please click on the button below.

ABOUT CROWD MOBILE 

Crowd Mobile is a global m-Content, m-Payments, m-Commerce, mobile entertainment and micro job company.

Crowd Mobile listed on the ASX in January 2015 through a back door listing into Q Limited (ASX: QXQ) and dual listed Frankfurt/XETRA June 2015.

To view the full announcement, please click on the button below.

Actinogen Medical US Roadshow Investor Presentation July 2016

15th July 2016, ASX Announcement

Focusing on an innovative approach, through the inhibition of cortisol production, for treating cognitive impairment in chronic neurodegenerative and metabolic diseases

Xanamem™:  A prime investment opportunity 

  • Alzheimer’s – a significant unmet need in a huge and growing global market
  • Xanamem™’s innovative, differentiated mechanism of action targeting the stress hormone cortisol
  • Evidence Xanamem™ is both symptomatic and disease modifying
  • Phase II study funded through to completion
  • Patent protected to 2031 – composition of matter
  • Value enhancing additional indications in substantive markets of interest to big pharmaceutical companies – Alzheimers disease, Diabetes, Parkinson’s disease

To view the full announcement, please click on the button below.

Analytica’s AutoStart Burette Granted US Patent

15th July 2016, ASX Announcement

Analytica (ASX:ALT) is pleased to announce that the AutoStart® burette system has been granted patent protection by the US Patent and Trademarks Office.

US Patent 9352080 has a priority date of 13 October 2005 and will expire on 17 Jan 2031, provided all renewal fees are paid.

CEO Geoff Daly said “Obtaining patent protection in the world’s largest medical device market is a major milestone and an important step in the commercialisation of the AutoStart infusion System. The patent process is lengthy and complex, with this national phase patent taking more than  10 years from the priority date. This patent is one of a number of AutoStart burette patents being pursued in the major medical device markets.”

To view the full announcement, please click on the button below.

iFAST Notification Of Results Release

14th July 2016, iFast Corporation

The Board of Directors of iFAST Corporation Ltd. (“the Company”) wishes to inform that the Company will release its unaudited financial results for the second quarter ended 30 June 2016 before market trading hours on 29 July 2016.

ABOUT IFAST CORPORATION 

iFAST Corporation Ltd. (“iFAST Corp”) is an Internet-based investment products distribution platform. Incorporated in the year 2000 in Singapore and listed on the SGX-ST Mainboard on 11 December 2014, iFAST Corp provides a comprehensive range of services, including investment administration and transactions services, research and trainings, IT services and backroom functions to banks, financial advisory firms, financial institutions, multinational companies, as well as investors in Asia. The company is also present in Hong Kong, Malaysia and China.

To view the full announcement, please click on the button below.

Bulletproof FY16 Results: Revenue up 67%, Closing Balance of $4.6m

14th July 2016, ASX Announcement 

FY16 Results Guidance

  • Full year revenues expected to be in line with market expectations $47m, up 67% on FY15
  • Underlying EBITDA expected to be $4.6m – $4.7, up from $4.2 in FY15
  • Underlying EBIT expected to be $600k – $700k, down from $850k in FY15
  • Positive operating cashflow, with closing cash balance of $4.6m

Bulletproof wishes to advise the market of its expected FY16 full year results and trading conditions with this interim update.

FY16 Results 

The ongoing investment in accelerated growth from organic and acquired revenue sources is expected to deliver a revenue figure in line with market expectations, at $47m, a 67% increase on FY15, and well above market revenue growth rates of 25-30%. Of this revenue, recurring sources are expected to make up close to 80% of the total figure. Cash flow is positive for the year, with a closing cash balance of $4.6m.

To view the full announcement, please click on the button below.

Folkestone Maxim A-REIT Securities Fund June 2016 Report: +4.02% Returned

For the month of June 2016, the Fund returned +4.02% (on an After Fee but Before Tax basis), outperforming the Fund’s Benchmark (S&P/ASX 300 A-REIT Accumulation Index) by 0.49%.

The June 2016 Monthly Report provides a snapshot of the Fund and the A-REIT sector’s performance.

Read more.

Fund Benefits

The Folkestone Maxim A-REIT Securities Fund is a high conviction, actively managed fund, that gives investors exposure to a mix of quality listed A-REITs that own assets across the retail, residential, commercial, industrial and real estate related social infrastructure sectors.

  • Investment Expertise
  • Exposure to Listed Real Estate
  • High Conviction, Active Strategy
  • Daily Liquidity
  • Quarterly Distributions
  • Strategic Capacity Limit

Download PDS.

Folkestone Exchanges Contracts for the Acquisition of Watermark Castle Cove

Folkestone’s (ASX:FLK) real estate funds management subsidiary, Folkestone Real Estate Management Limited (FREML), announced on 7 July 2016 that it had exchanged contracts for the acquisition of Watermark Castle Cove, an award winning retirement living community on Sydney’s lower north shore, the first asset for its seniors living platform and the Folkestone Seniors Living Fund No.1 (FSLF).

Mr Greg Paramor, Managing Director of Folkestone said “We already have more than $780 million in funds under management in social infrastructure through the ASX listed Folkestone Education Trust, Australia’s largest owner of early learning properties, and the unlisted CIB Fund which owns police stations and courthouses in Victoria. Our move into seniors living is a natural progression of our strategy to be a key player in the social infrastructure space.”

As Folkestone’s first seniors living fund, FSLF’s investment strategy is to own and develop high quality retirement living communities in Sydney via investing in operating facilities and/or partnering with quality operators to own and/or develop retirement living communities.

Strong Interest for Altech at the International Sapphire Industry Exhibition

14th July 2016, ASX Announcement

Highlights:

  • Strong interest for Altech’s entry into the high purity alumina market
  • Altech’s proposed nano particle size HPA product range well received
  • Vertically integrated  production model will ensure security of quality of HPA supply
  • Forecast tightening of supply side of the HPA market as demanded rapidly expands
  • HPA analytical and production data available to end-users on-line

Altech Chemicals Limited (Altech/the Company) (ASX: ATC) is pleased to provide a summary of its recent attendance at the 2nd International Sapphire Industry and Touch Screen Technology Exhibition in Shenzen, China (June 23-25 2016).

Altech’s presentation at the exhibition generated strong interest from synthetic sapphire producers, who welcome the prospect of the Company’s entry into the high purity alumina (HPA) market via its proposed 4,000tpa Malaysian HPA plant.

To view the full announcement, please click on the button below.

Mobotech Update June 2016: US Showcases & Demonstrations Continue; Last Investment Round Still Available

Another busy month showcasing and demonstrating the Mobots around the US.

Greg Ecker (President, Magline) and Steve Haythorne presented the Mobot to the 3PL & Chief Supply Chain Managers Summit in Chicago. This event was attended by 400+ senior logistic, retailer and manufacturing managers as a means to keep pace with innovation and meet with industry enablers to solve industry pains. The highlight for Mobotech were introductions to Wal-Mart’s and Kroger who were interested in the Mobotech solution for automating their last mile delivery system.

Mobotech also conducted demos to two key US companies based in Texas. Dean Foods, the biggest milk distributor in the US and Frito-Lay, a massive chips & dips, Pepsi owned Company. Both have last mile distribution issues that the Mobots potentially solve. They have since provided specs for Mobots and both are looking to schedule trials next month. As well as Dean Foods & Frito-Lay we also have trials being scheduled with Dollar General, PepsiCo and Saddle Creek Logistics coming up.

In order to support these trials, Magline have funded the shipping of the remaining four Mobots from NZ to the USA. They also now have the manufacturing and BOM plans to support the Mobots through these trials.

The last round still has NZ$200K available for investing should anybody wish to help with the final pre-sales push and take advantage of a de-risked opportunity.

ABOUT MOBOTECH

Mobotech design and build mobile robots (Mobots) for the fast moving consumer goods (FMCG) industry. The Mobot is a patented, smart, connected load transfer vehicle for use in logistic/supply chains to help save these companies millions in transportation costs, increase inventory control and injury prevention.